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ABSTRACT 
DEVELOPMENT OF RATIONALLY DESIGNED LIVE ATTENUATED VACCINES FOR LASSA FEVER AND 
VENEZUELAN EQUINE ENCEPHALITIS 
Dylan M Johnson 
May 9, 2020 
Lassa Virus (LASV) and Venezuelan Equine Encephalitis Virus (VEEV) are two single 
stranded RNA viruses belonging to the Arenavirus and Alphavirus families, respectively. Both are 
emerging pathogens without approved vaccines or treatments. VEEV is an important biothreat 
pathogen because it has been weaponized and is extremely infectious as an aerosol. VEEV 
causes biphasic febrile illness that can progress to a viral encephalitis with low mortality, but 
high morbidity. LASV causes a viral hemorrhagic fever, Lassa Fever (LF), which is endemic in 
West Africa, and responsible for between 100-500k annual infections with a 1-2% overall 
mortality rate. ML29 and VEEV TC-83 are well-described live attenuated vaccines based on LASV 
and VEEV, respectively. This work describes strategies to further attenuate and enhance the 
safety of ML29 and TC-83, an important step in preclinical development. 
VEEV V4020 was designed based on the stabilization of an E2 mutation, and 
rearrangement of the structural genes of TC-83. Here, VEEV V4020 is shown to be more 
attenuated than TC-83 based on IC inoculation in mice, and more phenotypically stable, in terms 
of pathogenicity, during serial passaging. 
ML29 is a reassortant virus combining the immune dominant glycoprotein (GPC) and 
nucleoprotein (NP) of LASV with the replicative machinery of to Mopeia virus (MOPV), a 
nonpathogenic relative of LASV. We provide evidence ML29 is safer and more immunogenic 
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than MOPV in STAT-1 deficient (STAT-1-/-) mice and Hartley guinea pigs. Additionally, Defective 
Interfering Particles (DIPs) from ML29 enhance vaccine immunity and attenuation in STAT-1-/- 
mice, and in intracranial inoculations of CBA/J mice. 
A potential mechanism of attenuation for ML29 is presented based on small RNAs 
detected from the ML29 L-segment by Northern Blot (NB). Furthermore, a unique RNA band was 
associated with DIP enriched ML29 was detected. A L-segment based Minigenome System (MG) 
for arenaviruses is described, which can be used for future analysis of the mechanism of 
replication for reassortant arenaviruses. 
The advanced safety data for both ML29 and VEEV V4020, described in this dissertation, 
combined with non-human primate efficacy studies described elsewhere, supports the 
advancement of both of these experimental vaccines to human clinical trials.  
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CHAPTER I 
INTRODUCTION 
Live Attenuated Vaccines (LAV) are responsible for many of the most successful 
vaccination campaigns, including the eradication of small pox (caused by Variola virus) and 
Rinderpest, and the near eradication of Polio [1]. LAVs have also proven useful for many other 
viral diseases including Influenza [2], Varicella Zoster Virus [3], Measles virus [4], Rotavirus [5], 
Ebola virus [6], and Yellow Fever virus [7], among others. 
LAVs are predominantly based on attenuation of the disease causing strain, however 
notable exceptions exist including the Vaccinia virus vectored small pox vaccine, and the 
vesicular stomatitis virus or adenovirus vectored Ebola virus vaccines [1, 6, 8]. While vector 
based vaccines have the advantage of increased versatility, they often engage the host immune 
system in different ways than the natural infection [9-11]. This can affect the magnitude and 
duration of host responses, along with the potential for the generation of vector focused 
immune responses [9-11]. Because of this, vaccines based on the naturally occurring pathogen 
are often preferred. However, because LAVs are often derived from pathogenic viral strains, 
concerns remain about the possibility of reversions to pathogenic phenotypes arising [12, 13]. 
This dissertation focuses on the development of LAVs that target two emerging single-stranded 
RNA viruses, Lassa virus (LASV) and Venezuelan Equine Encephalitis Virus (VEEV). Both of the 
LAVs are based on attenuation of their respective naturally occurring viruses.  
ML29 Live attenuated vaccine for LASV 
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Mopeia virus (MOPV), a virus closely related to LASV which does not cause pathogenesis 
in humans or non-human primates, has documented immunogenicity that spans across LASV 
genetic clades [14, 15]. However, MOPV is widely considered insufficiently attenuated for use as 
a LAV [15]. ML29, a genetic reassortant between MOPV and LASV (with antigenic determinants 
of LASV and the replicative machinery of MOPV,) is a leading LASV vaccine candidate that 
protects non-human primates (NHP) from fatal challenge [16-18]. Current approaches for LASV 
vaccine design are forgone in this introduction in favor of extensive discussion in Chapter II. In 
this dissertation, we test the hypothesis that ML29 is attenuated compared to MOPV, and 
examine the potential for the inclusion of defective interfering particles to further attenuate 
ML29 while enhancing the broadly protective immunogenicity of the LAV. 
Challenges for the development of safe and effective VEEV vaccines 
VEEV is maintained in avian and rodent species in South and Central America. It is a 
vector-borne virus, which is transmitted primarily by Culex mosquitos. When the mosquito 
subsequently transmits the virus to an equine while taking a blood meal, VEEV replicates to high 
levels, leading to fever, leukopenia, neurological disease, and up to a 83% mortality rate [19, 
20]. During the illness, high levels of viremia allow an infected equine to transmit the virus back 
to the mosquito vector allowing for subsequent rounds of infection, along with spillover into 
humans. Humans infected with VEEV typically experience a biphasic febrile illness, and malaise, 
which can be accompanied by severe headaches. In 4-14% of individuals, VEE will progress to a 
viral encephalitis resulting in clinical neurological symptoms, although VEEV has a low case 
fatality rate humans [19]. VEEV is grouped into six subtypes; however, epidemics have only been 
associated with subtype I, variants AB and C [21]. 
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Early research on VEEV resulted in a number of documented laboratory acquired 
infections, despite measures to prevent aerosol transmission [22]. The high rate of human 
infection following aerosol exposure, accompanied by the incapacitating nature of the illness 
lead to weaponization efforts by both the United States (US) and former Soviet Union [23]. As a 
result, in the US, VEEV is currently regulated under the Federal Select Agent Program as a 
biological agent that has the potential to pose a severe threat to both public health and safety 
and animal health and safety. 
The first VEEV vaccine efforts centered on formulations of formalin inactivated 
circulating VEEV IAB strains. Incomplete inactivation of these viruses led to vaccine-associated 
epidemics of VEEV IAB [19, 24, 25]. While the reservoir for VEEV IAB remains cryptic, VEEV IC 
strains periodically emerge through mutation in the ID strains [26]. The attenuated vaccine 
strain VEEV TC-83 was developed by passaging the virus in guinea pig hearts cell in culture while 
monitoring for virulence [13]. Although the introduction of VEEV TC-83 drastically reduced 
laboratory acquired infections [22], it has been stalled in Phase II clinical trials due to incomplete 
protection and the prevalence of adverse drug effects (ADE) that mirror some clinical features of 
wild-type disease [27-29]. Despite the high rate of ADE, including fever and headache [30], VEEV 
TC-83 is still used as an investigational new drug (IND) to vaccinate at risk laboratory workers 
and soldiers. 
Another negative aspect of VEEV TC-83 is that it often fails to induce protective 
immunity. A formalin inactivated form of VEEV TC-83, C-84, has been investigated for use as a 
standalone vaccine and to boost the immunity of non-responders to TC-83 vaccination [31]. 
Unfortunately, C-84 is poorly immunogenic and requires frequent re-vaccination [30, 32].  
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VEEV V3526, a rationally designed vaccine based on a lethal mutation in the PE2 
glycoprotein cleavage site, along with a suppressor mutation in the E1 glycoprotein at position 
253, is immunogenic and protective. Yet VEEV V3526 remains deeply attenuated in mice, 
equines and non-human primates [33-36]. Additionally, VEEV V3526 appears to result in less 
adverse drug reactions in mice and non-human primates than VEEV TC-83 [35, 36]. Despite great 
promise, the VEEV V3526 failed in phase I clinical trials due to unacceptable reports of moderate 
to severe fever following vaccination [32]. 
Recently, chimeric alphaviruses have been considered as LAVs to protect against VEEV. 
A chimera generated from the structural proteins from VEE combined with the replicative 
machinery of a related alphavirus with low pathogenicity in humans, Sindbis Virus, was 
attenuated in mice while providing protecting from lethal VEEV challenge [21, 37]. A similar 
construct for Eastern Equine Encephalitis protected non-human primates (NHP) from a lethal 
aerosol challenge [38]. Eilat Virus (EILV) is an alphavirus that only replicates in mosquitos, and is 
unable to infect mammalian or avian cells in culture due to host restriction for both entry and 
RNA replication [39, 40]. Chimeric viruses with EILV replicative machinery and VEE structural 
proteins were safe in mice, and protected them from lethal VEEV challenge [41]. However, in 
this case, the chimeric virus is functioning more as a replicon than a LAV, as it likely does not 
replicate following vaccination. Additionally, EILV can interfere with VEEV replication potentially 
extending the window for use of this chimeric vaccine in post-exposure prophylaxis [41, 42]. 
VEEV V4020 is a vaccine candidate based on VEEV TC-83 with rearrangement of the 
structural genes, a stabilizing mutation in the key E2-120 glycoprotein attenuating mutation, and 
the addition of a second subgenomic 26S promoter, leading to glycoprotein and capsid genes 
being produced independently [43, 44]. The additional promoter likely changes the ratio of 
glycoprotein to capsid production in vivo, which could interfere with viral particle assembly. 
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Previously, we showed that VEEV V4020 provided complete protection with sterilizing immunity 
following lethal challenge of VEEV-TrD in mice [44]. Here, we test the hypothesis that VEEV 
V4020 is attenuated compared to VEEV TC-83 in terms of neuro-virulence in mice, and that it 
has reduced capacity for reversion to a pathogenic phenotype compared to TC-83. 
In this work, we provide evidence to support the overarching hypothesis that LAVs for 
LASV and VEEV, based on their respective natural pathogens, are safe and immunogenic. 
Additionally, two methods to enhance the immunogenicity and safety of the vaccine candidates 
are tested: the inclusion of defective interfering particles for the enhancement of the ML29 
vaccine, and the rearrangement of structural genes for enhancement of the Venezuelan Equine 
Encephalitis Virus (VEEV) TC-83 vaccine. Advanced small animal models are used to compare the 
safety and immunogenicity of ML29, defective interfering particle enhanced ML29, and VEEV 
TC-83, and VEEV V4020. 
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CHAPTER II 
NEW CHALLENGES FOR DEVELOPMENT OF A LASSA FEVER VACCINE WITH FULL COVERAGE 
Lassa virus (LASV) is the most prevalent African arenavirus, existing in nature as a 
persistent infection of rodent hosts. In particular, Mastomys natalensis, which are widely spread 
in sub-Sahara Africa. While LASV does not affect its natural host, rodent-to-human transmission 
can result in Lassa Fever (LF) disease with high mortality rates in vulnerable groups. Recent 
improvement in virus detection and rodent host identification provided evidence of LASV 
expansion outside of traditional endemic areas including Nigeria, Guinea, Liberia and Sierra 
Leone. Recently, Nigeria experienced the largest ever LF outbreak with an unusually high case 
fatality rate of 27% in 2018 and 20.4% in 2019. The World Health Organization (WHO) included 
LASV in top priority pathogens, and released a Target Product Profile (TPP) for LASV vaccine, 
which raised challenges for vaccine developers to produce a vaccine with pan-LASV coverage. 
Rationally designed and platform-based vaccine candidates will be overviewed, and how they 
will meet the WHO’s TPP criteria for development of a prophylactic LASV vaccine with full 
coverage will discussed.  
Introduction 
Lassa virus (LASV) is a rodent-borne human pathogen from the Arenaviridae family. 
Currently, the family includes four genera, Antennavirus, Hartmanivirus, Mammarenavirus, and 
Reptarenavirus [45-47]. These viruses infect fish (antennaviruses), snakes (hartmaniviruses and 
reptarenaviruses) and rodents (mammarenaviruses). LASV belongs to the Old World group (OW 
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or Lymphocytic Choriomeningitis Virus, LCMV-LASV serocomplex) of the genus 
Mammarenavirus.  
Mammalian arenaviruses have 2 genomic single-stranded ambisense RNA segments. 
The L RNA encodes large L (RNA-dependent RNA polymerase) and small RING finger Z (matrix) 
proteins. The S RNA encodes a nucleoprotein (NP) that tightly associates with viral RNA, and a 
glycoprotein precursor (GPC), which is processed into three subunits: the stable signal peptide, 
SSP; the receptor-binding GP1; and the transmembrane GP2, which is responsible for fusion 
with cell membrane. All three subunits are non-covalently linked to form trimeric features on 
the virion surface [48]. Surface GPs are extensively glycosylated and complex pattern of this 
glycosylation complicates development of GPC-based vaccines [45, 49-51].  
LASV originated in Nigeria about 800-1000 years ago and gradually moved westward 
during the last few centuries [52-54]. LASV viral polymerase was identified as a major positive 
selection target during this migration [55]. The LASV species represent a collection of genetically 
heterogeneous isolates from rodents and humans, resulting in their placement into 6 genetic 
lineages based on geographic location. The most heterologous LASV strains circulates in Nigeria 
(lineages I-III) and Guinea, Liberia and Sierra Leone (lineage IV) with sequence inter-lineage 
diversity up to 24.6% [45, 53, 54, 56]. A fifth lineage has been proposed for LASV isolates from 
Mali and Ivory Coast [54, 57]. An isolate from a cluster of human infections epidemiologically 
linked to Togo was proposed to represent a lineage VI [58].  
Persistently infected multimammate rats (Mastomys natalensis spp.), a widely spread 
and genetically diverse rodent species in Sub-Sahara Africa, are the major source of LASV 
infection which can vary from asymptomatic or flu-like disease to fatal Lassa fever (LF) 
responsible for thousands of death annually. With the exception of dengue fever, the estimated 
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global burden of LF is the highest among the viral hemorrhagic fevers [59]. In contrast to poorly 
predicted EBOV outbreaks, LASV infection is endemic in West African countries, representing 5% 
of the total world population, including the most populated Nigerian state [60, 61]. New 
epidemiological studies indicate that LASV endemic regions are expanding [62]. One 
environmental-mechanistic study predicts that the number of LASV infections will double from 
the current levels in coming years [63]. Taking into consideration the impact of LASV infection 
on public health in endemic areas, the WHO included LASV in its top-priority pathogens list, and 
released a Target Product Profile (TPP) for LASV vaccine development [64]. In 2018, the US Food 
and Drug Administration (FDA) added LASV to their priority review voucher program. 
The WHO’s TPP is focused on a preventive vaccine for the safe protection of healthy 
adults and children, with a duration of at least 3 years, against LASV strains from the major 
genetic lineages, I-IV. The WHO’s prequalification requirement included in this TPP indicated the 
preferred vaccine candidate must be inexpensive, safe, highly efficacious, heat-stable, multi-
antigen, and user- and environmentally friendly. Here, we will review the current status of LASV 
vaccine research focusing on several challenging areas of pre-clinical and clinical development.  
LASV genetic diversity likely contributes to the underestimating of its prevalence in West 
Africa [65, 66] and seems to be also associated with wide range of clinical manifestations and 
outcomes in different endemic areas. LASV diversity represents a huge challenge for diagnostics 
and vaccine development [67]. Currently, there is no licensed vaccine against LF and therapeutic 
options are limited to off-label use of Ribavirin.  
2. Rodent-to-human transmission
Although M. natalensis species are widely spread in sub-Sahara Africa, LASV infection is 
predominantly confined to M. natalensis monophylogenic group A-I in West Africa [68]. Other 
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host phylogroups from Central and Southern African regions have been associated with non-
pathogenic Mopeia (MOPV), Morogoro (MORV), Gairo (GAIV) and Luna (LUNV) mammalian 
arenaviruses [69-72]. In these areas, LASV has not been found, and LF cases have never been 
reported. MOPV has been considered as a “natural LASV vaccine” since experimentally 
immunized non-human primates (NHPs) were fully protected against fatal LF [15, 73, 74]; and 
thus, the MOPV genetic backbone was used to rationally design promising LASV vaccines [17, 
75]. 
Natural rodent-to-human transmission of LASV occurs primarily via inhalation or/and 
ingestion of dusts contaminated with excreta of infected rodents [76-79]. The peri-domestic life 
style of M. natalensis, house design, and poor sanitation in rural areas provides an ideal 
environment for rodent activities at night, and even during the day [80, 81]. Rodent excreta in 
food stocks and consuming rodents meat have been identified as major risk factors of LASV 
transmission [77]. Clusters of infected M. natalensis are responsible for the spatial distribution 
of LF cases in endemic areas [63, 82-84]. In LASV endemic areas, contaminated rodent excreta is 
a source for the natural infection of NHPs as recently documented in Southern Nigeria [85].   
3. Mucosal routes of LASV infection
Mammarenaviral infection is dependent on directional exposure to, and release from, 
polarized epithelial cells. The pattern of LASV interaction with its target cells during entry can 
drive the pathogenicity observed during natural infection [86, 87]. In polarized renal epithelial 
MDCK cells, LASV entry occurred more efficiently from basolateral surfaces, while matured virus 
particles were predominantly released apically [88]. A basolateral route of entry suggests that 
the virus can only access cell receptors when the integrity of the epithelial barrier has been 
compromised [89]. The relation of the in vitro LASV – receptor interaction pattern to renal 
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dysfunction in LF patients in Nigeria, [90] and virus shedding in urine [81], remains to be 
elucidated.  
The microbial community associated with the gastro-intestinal mucosa may affect 
susceptibility to LASV infection. Pre-exposure of epithelial cells to Salmonella enterica promoted 
the entry of lentivirus pseudo particles expressing LASV GPs [91]. This finding suggests that the 
high burden of Salmonella infections in Africa can be an additional risk factor for individuals 
living in LASV endemic areas [92]. 
Polarized epithelial cells serve as a barrier restricting virus infection [93]. Accumulating 
evidence indicates that crossing a healthy epithelia barrier at site of the infection can contribute 
to virus attenuation. In a surrogate model of LF in NHPs, LCMV-WE54 applied systemically 
(intravenously) always resulted in fatal LF-like disease. However, oral application (lavage) 
resulted in limited infection, and the development of protective immunity [94-96]. LASV 
infectivity was only marginally decreased at pH 4.0  [97], which suggests that the low pH gastric 
environment does not substantially affect LASV infectivity. If so, this observation indicates 
rodent-to-human transmission via the gastro-intestinal tract as one of the major routes of 
natural infection [76, 77]. 
Gastric infection may confer natural immunity to LASV. Experimentally, mice orally 
immunized with recombinant S. typhimurium expressing LASV NP were protected against lethal 
LASV challenge [98]. Similarly, hamsters experimental inoculated intragastrically with Puumala 
virus (PUUV), a rodent-borne hantavirus causing hemorrhagic fever with renal syndrome (HFRS), 
developed protective immunity against lethal PUUV challenge [99]. These observations suggest 
that the high resistance of LASV to low pH environments may be an adaptation that facilitates 
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transmission via alimentary tract because it results in benign infection and protection from fatal 
disease.  
Human-to-human transmission is estimated to be responsible for about 20% of LASV 
infections. It is the major mechanism of transmission during nosocomial outbreaks, and is often 
associated with a few infected individuals, referred to as “super-spreaders” [100, 101]. The 
mechanism of super spreading is not clear and remains to be elucidated. In addition, persistence 
of the virus in urine, combined with poor sanitation practices, can facilitate LASV transmission 
during nosocomial outbreaks.   
4. LASV cell receptor usage diversity
After crossing an epithelial barrier, LASV targets macrophages and dendritic cells (DCs) 
and via the blood stream (viremia), leading to infection of many different tissues and organs 
(pan-tropism). The major cellular receptor for LASV, MOPV, and LCMV and some NW 
mammalian arenaviruses is α-dystroglycan, αDG [102]. The αDG protein is non-covalently linked 
to a transmembrane subunit, βDG, which transduces signals from the Extra Cellular Matrix 
(ECM) to the intracellular cytoskeleton. Like-acetylglucosaminyltransferase mediated O-
mannosylation is crucial for the αDG interaction with GP1, as well as for the interaction of αDG 
with its natural ligands [103-105]. The strength of LASV GP1 binding affinity to αDG can be partly 
correlates with pathogenicity. The affinity of LASV and LCMV-WE54 GP1 to αDG was 2-3 logs 
higher than those of the non-pathogenic viruses MOPV and LCMV-ARM [106]. Notably, viral GP1 
binding results in down-regulation of functional αDG on cell surface, which can affect cell-to-cell 
interaction (e.g., interaction of DCs with T lymphocytes) [105, 107]. 
While the αDG is the major cell receptor for LASV, the usage of this receptor is cell- and 
tissue specific depending on O-mannosylation, additional signaling interactions (e.g., cellular 
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receptor tyrosine kinases, p21-activating kinase), and proper interaction with DG-associated 
proteins (e.g., utrophin, β-dystrobrevin, β2-syntropin, sarcoglycans) [108, 109]. In cells lacking 
functional αDG (e.g., mature hepatocytes), additional molecules,  DCs-specific adhesion 
molecule (DC-SIGN), liver and lymph node sinusoidal endothelial cell C-type lectin, and Axl and 
Tyro3, two members of the TAM (Tyro3, Axl, Mer) family, promote αDG-independent LASV 
infection in vitro [110, 111]. In marmosets, the Nigerian LASV/803213 strain induced 
upregulation of Axl-1 in the liver promoting virus replication and pathological hepatocyte 
proliferation, contributing to arenavirus-induced liver pathology.  
TAM receptors and their ligands (e.g., Gas6, protein S) play an essential role in apoptotic 
cell clearance, damping immune responses, and in coagulation pathways [112, 113]. DC-SIGN 
and LSECtin lectins can also serve as LASV attachment factors on monocyte/macrophages and 
DCs, early targets of LASV infection [111]. These targets seem to be crucial for the induction of 
host responses via TLR2/TLR6/CD14 engagement and, Mal/Dy88- and NF-κB-mediated innate 
immunity pathways [114]. This engagement can contribute to strong innate NF-κB-mediated 
pro-inflammatory and adaptive immune responses [114, 115]. Despite all this receptor usage 
complexity, it is becoming clear that receptor engagement induces an array of cell responses 
that results in internalization of the virus, while also orchestrating of the host cell response. 
Upon engagement of the cell receptor, LASV and LCMV enter susceptible cells using an 
unusual pathway, which is independent of clathrin, caveolin, and actin, factors required for the 
“classical” endocytic pathway employed by the NW mammalian arenaviruses (e.g., JUNV, 
MACV). Recent studies demonstrated the involvement of a micropinocytosis-like mechanism in 
LASV entry [108, 116]. It was documented that several micropinocytosis-associated kinases, 
epithelial and hepatocyte growth factor receptors (EGFR and HGFR), and sodium hydrogen 
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exchangers (NHE), were required for LASV entry. However, in contrast to “classical” inducible 
micropinocytosis, LASV entry did not induce morphological changes in host cells.  
When virus-containing vesicles are delivered to late endosomes/lysosomes, LASV GP1 is 
dissociated from αDG and binds LAMP1 (Lysosome-Associated Membrane Protein 1) to initiate 
membrane fusion [117]. All LASV strains share the GP1 amino acid residues required for LAMP1 
binding, but these residues have not been found in LCMV and MORV. This suggests that among 
genetically related mammalian arenaviruses, the requirement of LAMP1 is a unique feature of 
LASV [117, 118]. LASV GP1 binds N-glycosylated LAMP1 carrying α-2,3-linked sialic acid (SA) in 
the upper airway of rodents, promoting the horizontal transmission of LASV in the natural 
reservoir. Meanwhile, α-2,6-congugated SA in the human upper airway seems to limit human-
to-human transmission. Interestingly, EBOV entry also is critically dependent on the late 
endosomal/lysosomal protein NPC1 (Niemann-Pick disease type C1 protein), suggesting that this 
“receptor switch” mechanism can contribute to virus-host interaction and viral tropism in both 
highly pathogenic infections [119]. 
The extensive LASV glycan shield on the LASV surface (which comprises ~ 25% of the 
glycoprotein mass) efficiently protects vulnerable GP1 sites involved in interaction with αDG, 
LAMP1, and the GP2 fusion loop from a humoral antibody response [48, 120]. This shield 
contains an abundance of unprocessed glycans forming spatially distinct clusters, protecting 
crucial GP1 and GP2 sites. Evolutionary limited amino acid diversification around these clusters 
supports their role in immune evasion [48, 53]. The presence of unprocessed oligomannose-type 
glycans, and the importance of native quaternary LASV glycoprotein structures, are real 
challenges for the development of recombinant vaccine candidates based on the expression of 
LASV GPC, since current expression technologies poorly mimic the native trimeric architecture 
and glycosylation patterns of mature LASV particles [48].   
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5. LASV biological diversity and variation in LF clinical manifestations
LASV is a rodent-borne virus, and LASV infection is handled differently by the immune 
system of rodents, humans, or NHPs. Not surprisingly, LASV isolates from LF patients with 
different clinical outcomes showed a weak correlation between the severity of human disease 
and virulence in experimentally infected guinea pigs [121, 122]. Most studies in animal models 
were performed with LASV/Josiah/SL/76/H (LASV/JOS) or related viruses from lineage IV [123]. 
LASV/JOS and the Nigerian LASV/803213 (lineage II) are highly pathogenic in strain 13 Guinea 
Pigs (S13GPs) and NHPs, but not in  outbred Hartley Guinea Pigs (OHGPs) [122, 124] [125] [126]; 
while the LASV/GA391 (lineage III) causes fatal infection in OHGPs [127]. The LASV/LP, the 
prototypic strain from lineage I, induced only mild weight loss in S13GPs [128].  Notably, a LASV 
isolate from Mali which is estimated to have separated from lineage IV around 200-300 years 
ago, was only partially lethal in STR13GPs and NHPs [129]. 
Our knowledge of the natural history of LASV infection in humans is mainly based on 
limited clinical studies in Sierra Leone and Liberia performed in the late 1970-1980’s [130-133]. 
A prospective case-control study of 441 confirmed LF patients established that the best 
predictors of disease are a combination of fever, pharyngitis, retrosternal pain and proteinuria 
[131, 134]. The best predictors of clinical outcome were fever, sore throat, and vomiting. 
Meanwhile, a prospective cohort study in Guinea, where LF was infrequently recognized, failed 
to identify specific predictors of poor clinical outcomes [135]. Progressed LF in children included 
widespread edema, abdominal distention, and bleeding (“swollen baby syndrome”) [136].  
During 1969-2016, 33 imported cases of LF were documented in travelers arriving to non-LASV-
endemic countries from West Africa [137]. Non-African individuals seem to be more sensitive to 
LASV infection, and most of them developed more distinctive clinical features (fever with 
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pharyngitis, sore throat, tonsillitis, conjunctivitis, oropharyngeal ulcers, or proteinuria) [135, 
137]. 
In progressed LF patients, elevated levels of AST in plasma and high viremia were 
strongly associated with death [135, 138]. High AST/ALT ratios suggested substantial 
involvement of non-hepatic tissues in pathogenesis of the disease. In patients with fatal 
outcomes, updated clinical observations revealed  low or undetectable levels of the pro-
inflammatory chemokines, IL-8 and IFN-inducible IP-10 [139]. Elevated levels of TNF-α receptors 
and IL-6 were associated with fatal LF. Elevated levels of IL-6 in plasma is currently being 
considered as the third biological marker of fatal LF associated with hepatic regeneration [135, 
140-142]. Likewise, low levels of IL-6, IL-10, CD40L, AST, ALT, ALP, and BUN in Sierra Leonean LF 
strongly correlated with survival [135, 143].  
The first cases of LF in Sierra Leone were described as LASV hepatitis, and limited 
postmortem histological studies indicated that the liver was one of the most affected organs 
participating in a systemic breakdown  [140, 144]. With minimal inflammation, hepatocellular 
necrosis and active hepatocyte proliferation was found in the livers of LF patients. However, the 
degree of liver damage was not sufficient to implicate hepatic failure as the primary cause of 
death. The hepatocyte proliferation observed in LF patients from Sierra Leone was also 
observed in NHPs experimentally infected with LASV/JOS and Nigerian LASV/803213 [126, 142]. 
However, in spite of strong proliferative signals, LASV did not induce hepatic hyperplasia. In a 
marmoset model of arenavirus-induced hepatitis, the infection triggered hepatocyte 
proliferation, which aborted in G1/S transition of the cell cycle [67, 142, 145]. Expression of non-
conventional receptors (Axl-1, Tyro3, DC-SIGN, LSECtin), and stimulation of oval cells 
(hepatocyte progenitors expressing αDG), promoted virus replication in hepatocytes. This NHP 
model of arenavirus-induced liver pathology may be helpful to gain insight into mechanisms of 
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pathophysiological hepatic proliferation, and can explain the high levels of AST and ALT in LF 
patients and the contribution of the liver to LF pathogenesis.  
A recent retrospective observational study on 291 LF patients treated in the Irrua 
Specialist Teaching Hospital, Edo State, Nigeria revealed some similarities and differences 
between LF in Sierra Leone and Nigeria [90]. In both studies, the liver was clearly involved in 
pathogenesis as lower AST/ALT ratios (of 1.5) among Nigerian patients were more consistent 
with hepatocyte-affecting arenavirus infection [145]. Likewise, higher viral loads detected by 
qRT-PCR strongly correlated with poor outcome [146]. However, in contrast to Sierra Leonean 
LF, sepsis-associated hypothermia rather than fever was a predictor of poor outcome in Nigerian 
patients. In addition, LF patients under 5 years old or over 55 years old were at greatest risk for 
death [90, 147]. Prospective clinical and epidemiological observations provided evidence that 
Nigerian strains were associated with more severe LF disease than strains from clade IV (Guinea, 
Liberia, and Sierra Leone). The fatality rate among hospitalized LF patients in Nigeria, 30-50%, 
was almost 2-fold higher than among patients from other LASV endemic areas [81, 146, 148, 
149]. 
The 2018 LF outbreak in Nigeria was the largest on the record, and affected 20 states 
across country with an overall case fatality rate of 25.1%, which is unprecedentedly high for 
natural “rural” LASV infection [150]. The majority of cases (81%) were from the three southern 
states, Edo, Ondo, and Ebonyi. Among the confirmed cases, the most common clinical 
manifestations were fever, headache, vomiting, fatigue, and abdominal pain. While hemorrhage 
signs were rare (17%), these signs, as well as unconsciousness and age (41-60 years), were 
significantly associated with fatal outcome. Higher fatality rates in older Nigerian LF patients 
were documented in several studies, which was a clear departure from observations in Sierra 
Leone where mortality among 60+ year old patients was lower than children [90, 146, 150].  
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The most striking clinical feature of the recent Nigerian LF outbreak was renal 
involvement, since elevated creatinine and blood urea were associated with fatal outcome [90]. 
The acute kidney damage in Nigerian patients seemed to be an intrinsic feature of LASV 
infection, rather than a complication of the disease. Whether the extent of renal involvement is 
a specific feature of Nigerian LF has yet to be further elucidated. The heterogeneity of LASV 
strains from clade II which circulate in the Edo state does not exclude the possibility that some 
of these viruses uniquely cause kidney damage [146].  
Non-Nigerian LASV strains also have the potential to induce kidney pathology. LASV/JOS 
exposure of human blood mononuclear cells affected the expression of genes involved in 
coagulation pathways including upregulation of HBEGF (heparin-binding epidermal-growth-
factor-like growth factor) which is associated with renal failure and glomerulonephritis [78, 151]. 
Among other genes involved in coagulation, the strong upregulation of THBD (thrombomodulin) 
could explain why disseminated intravascular coagulation (DIC) is rare in LF patients in 
comparison with other viral HFs [78]. 
The 2018 increase in LF cases in Nigeria was not associated with a particular LASV strain.  
Phylogenetic analysis revealed that LASV genomes were from lineage II (93% of genomes) and III 
with relatively high diversity. It has been estimated that both lineages split from a common 
ancestor more than 200 years ago, and remained stably separated in rodent populations, 
presumably by natural barriers formed by the Niger and Benue Rivers [152]. Genomic analysis 
also did not find evidence of a substantial contribution of human-to-human transmission in the 
recent outbreak which seems to be more related to improvements in diagnostics and public 
awareness rather that changes in epidemiology of the disease. 
6. Correlates of protection during natural LASV infection
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In LF patients, the development of LASV antibodies are not associated with viral 
clearance, survival, or positive prognosis. High viremia, and high IgM and IgG titers often coexist 
in LF patients. At the time of hospital admission, LASV antibodies against NP or GPs were not 
associated with survival or positive prognosis. In contrast, patients simultaneously containing 
LASV antigen and specific IgM antibodies had significantly higher chances (>4 times) to die in 
comparison with patients with IgM antibodies alone [143, 153]. In some surviving patients, LASV 
IgM antibodies can persist for a prolonged time, suggesting that a broken IgM/IgG switch is a 
part of pathogenesis [143, 154]. In most cases of natural LASV infection, humoral responses 
(predominantly against LASV NP) have a short lifetime, and antibody titers decline below 
detectable levels within a few months [155, 156]. In clinical trials, human convalescent plasma 
did not protect recipients [138]. Although LASV humoral responses do not play a role in 
controlling LASV during natural infection, human LASV antibody generated from B cells of LASV-
infected individuals can be useful for post-exposure treatment [157, 158]. These neutralizing 
antibodies locked LASV glycoprotein complex in a pre-fusion conformation and prevented the 
rearrangements required for interaction with LAMP1 binding and membrane fusion. 
There is a widely accepted perception in the field that protective immunity during 
natural LASV infection in healthy individuals is predominantly associated with T cell responses 
[59, 159-161]. In long-term LF survivors, and in experimentally infected NHPs, early and robust 
virus-specific T cell responses correlated with recovery and protection [15, 141, 162-164]. 
Consistent with these findings, depletion of CD8+ T cells completely abolished the protection of 
vaccinated animals, whereas CD4+ T cell depletion only resulted in partial protection [165, 166]. 
LASV specific protective CD8+ and CD4+ T-cell subsets were poly-functional, cross-reactive and 
cross-protective [17, 165-168]. Likewise, in a nurse who acquired LF in Togo, and was treated at 
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Emory University Hospital, recovery was consistent with the development of long-term  poly-
functional LASV-specific T cell responses [169].  
LASV survivors had strong CD4+ T cell proliferative responses against LASV NP and GP2 
epitopes [163, 164]. Importantly, these responses were not only LASV strain-specific but were 
also broadly cross-reactive, potentially contributing to protection against heterologous LASV 
strains. These observations are in line with previous results, which documented the role of LASV 
NP and GP2 epitopes in induction of CD4+ T cell-based cross-reactivity and cross-protection in 
NHP and rodent models [98, 170]. NP is the major structural factor of the arenavirus 
transcription/replication machinery complex, and is synthesized during early stages of the 
infection, prior to GPC. Together, these studies indicate that early, strong anti-NP immunity is 
crucial for effective viral control and vector immunogenicity [171, 172].  
7. Rationally designed LASV vaccine candidates
Epidemiological evidence indicates that LF survivors acquire long-term protection 
against manifested LF disease, indicating that a live attenuated virus (LAV) platform represents 
the most effective approach to control LASV. Methods used in the past to create very effective 
LAV vaccines against yellow fever, polio, measles, mumps and other infections, are generally not 
preferred under current regulatory environment and guidelines, due to the intractability of 
generating attenuated strains by serial passaging. However, remarkable advances in 
biotechnology and molecular virology have brought renewed interest to the new generation of 
LAV vaccines. These vaccines are safe, efficacious and cost-effective (e.g., the human-rhesus 
reassortant vaccine against rotavirus infection, RotaShield, licensed for use in the US in children 
at 2-6 months of age) [173]. 
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The safety and efficacy of several LASV vaccine candidates based on vaccinia virus [15, 
127, 174], MOPV [16-18], alphavirus replicons [175, 176], VSV [167, 177] , and yellow fever 17D 
[178, 179] vectors were tested in NHPs (Table 1). The major features of these vaccine candidates 
and new approaches based on LASV reverse genetics were discussed recently in several reviews 
[59, 161, 180-182]. This subsection will focus on the most challenging areas of LASV vaccine 
research and development: addressing LASV heterogeneity, correlates of protection, safety in 
immunocompromised individuals, and regulatory pathways. 
8. LASV antigens required for induction of broad cross-reactive and long-lasting protective
immunity 
The first experimental vector-based LASV vaccine expressed NP antigen of 
LASV/GA391/NIG/96/H (clade III) in vaccinia virus (Vv, Lister strain) [127]. This vaccine did not 
induce detectable LASV antibodies before challenge, but completely protected Hartley guinea 
pigs against fatal LF disease [127]. All other experimental LASV vaccines were designed based on 
LASV/Josiah (clade IV). In strain 13 guinea pigs, 94% and 74% of animals vaccinated with 
recombinant Vv (strain NYBH) expressing LASV/JOS NP or GPC were protected against 
homologous challenge, respectively [183]. Similarly, LASV/JOS NP expressed via alphavirus RNA 
replicons fully protected strain 13 guinea pigs against fatal LF disease [175].  In contrast, in the 
same challenge model, LASV NP expressed in an rVSV vector provided only partial protection 
against LASV/JOS [128]. 
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Table 1. Contributions of anti-NP and –GPC adaptive immune responses in the protection of 
guinea pig and NHP challenge models of Lassa fever 
Vaccine 
Vector, 
Dose, Route 
Antigen/Challenge Animal 
Model 
Protection/ 
Viremia 
CMI Humoral 
immunity 
Ref 
Vv, Lister, 
1x107.5 PFU, 
single dose, 
NP, GA391 
(III)/GA391a 
Hartley GPs 100%/- CMI? No nAbs [127] 
Vv, NYBN, 
single dose 
NP, Josiah/JOS(IV) STR13GPs 94%/+ CMI? No nAbs [183] 
Vv, NYBN, 
single dose 
GPC, JOS/JOS STR13GPs 74-100/+ CMI? No nAbs [174, 
183] 
LASV Z-158b, 
1x103.7 PFU, 
single dose 
All Z158 
antigens/JOS 
STR13GPs 100%/- CMI, 
spleen 
transfer 
exp. 
Immune 
plasma 
did not 
protect 
[122] 
VEEV-RNA 
replicon, 
1x107 IU, 3 
injections 
NP 
GPC 
NP+GPC, JOS/JOS 
STR13GPs 100%/- 
100%/- 
100%- 
CMI Immune 
plasma 
did not 
protect 
[175] 
MOPV/LASV 
(ML29), 
1x103, single 
dose 
NP&GPC, JOS/JOS, 
803213(II) 
STR13GPs 100%/- (for 
JOS 
challenge) 
100%/+ 
(for 803213 
challenge 
CMI No nAbs, 
IgG Abs 
[17, 
125] 
YF17D/LASV, 
1x105 PFU, 
single dose 
GPC, JOS/JOS STR13GPs 80%/+/- CMI? No nAbs, 
IgG Abs 
[178] 
rVSV/LASV, 
1x106 PFU, 
single dose 
GPC, JOS/JOS, Z-
132, Soromba-R 
STR13GPs 100% 
(against 
JOS and Z-
132 
challenge) 
ND No nAbs, 
IgG Abs 
[128, 
184] 
rVSV/LASV, 
1x105 PFU, 
single dose 
NP, JOS/JOS STR13GPs 66.6% ND ND [128] 
DNA, 300 µg, 
3 injections, 
IMEP or IDEP 
GPC, JOS/JOS STR13GPs 80-
100%/+/- 
CMI? nAbs, low 
titers 
[185] 
Rc-
LASSARABV, 
1x106 FFU, 
single dose 
GPC, JOS/JOS-GP Hartley GPs 40% ND No nAbs, 
IgG Abs 
[184] 
LASSARAB, 
killed, with 
GPC, JOS/JOS-GP Hartley GPs 80%/+++ No nAbs, [184] 
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TLR4 agonist, 
3 injections 
non-nAbs 
involved 
in ADCC 
LASV, VRP, 
1x107, SC 
All LASV/JOS 
proteomsc/JOS 
STR13GPs 100%/- CMI No IgM 
or IgG 
before 
challenge 
[186, 
187] 
LASV/JOS, 
killed, 
multiple 
injections 
All LASV 
proteoms/JOS NHPs 
(cynos) 
0% No nAbs, 
IgG Abs 
(anti-NP, 
-GPC) 
[188] 
MOPV, 
single dose, 
All MOPV 
proteoms/JOS 
NHPs 
(rhesus) 
100%/- ND ND [15, 
73, 
74] 
Vv, NYBN, 
single dose 
NP 
GPC 
NP&GPC,JOS/JOS 
NHPs 
(rhesus, 
cynos) 
27% 
85%/++ 
100%/+ 
CMI [15] 
rVSV, 1x106 
PFU, single 
dose 
GPC, JOS/JOS NHPs 
(cynos) 
100%/++ nAbs [167] 
ML29, 1x103 
PFU, single 
dose 
GPC&NP, JOS/JOS, 
LCMV-WE 
NHPs 
(rhesus, 
marmosets) 
100%/- 
(against 
LASV/JOS 
and LCMV-
WE 
CMI No nAbs [16, 
17, 
161, 
168] 
MOPEVACLAS, 
single dose, 
6x106 FFU, 
SC 
GPC, JOS/JOS NHPs 
(cynos) 
100% CMI nAbs [75] 
DNA, 10 mg, 
4 sites, 2-3 
injections, 
IDEP 
GPC, codon 
optimized, JOS/JOS 
NHPs 
(cynos) 
100%/- CMI nAbs, IgG [189, 
190] 
Efficacy trials in NHPs (Macaca mulatta and M. fascicularis) with rVv expressing 
different LASV genes documented that both GPC subunits, GP1 and GP2, are required for 
protection [15, 191]. In contrast to results in guinea pigs, vaccination with rVv-NP protected only 
3 of 15 NHPs (22%). Nevertheless, the highest level of the protection was observed when NHPs 
were vaccinated with rVv expressing both genes, NP&GPC, simultaneously [15]. In addition, 
while Vv vectored vaccine formulations failed to induced sterilizing immunity, the lowest level of 
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post-challenge viremia was observed in NHPs immunized with Vv-NP&GPC. Similar to guinea 
pigs, protection in NHPs was not associated with humoral immune responses [15, 156]. 
These results indicate that expression vectors and animal challenge models have an 
effect on the results of vaccine efficacy trials. In terms of antigen formulation, there is a 
consensus that expression of LASV GPC is required and sufficient for solid protection. While anti-
NP immunity in rodent models is highly protective, it is still not enough to protect NHPs, 
suggesting different contributions of anti-NP immunity in viral control between rodents and 
NHPs. The positive impact of anti-NP immunity on viral control at an early stage of the infection 
is well anticipated because NP plays the central role in transcription/replication [192]. NP 
together with L protein are the two minimal trans-acting factors required to rescue LCMV and 
LASV from recombinant cDNAs [193, 194]. Detection of broad cross-reactive anti-NP CD4+ T 
cells in LF survivors suggests contribution of these cells in long-term protection against LF 
caused by LASV strains from different clades. Among LASV advanced vaccine candidates (tested 
in NHPs), only ML29 has the ability to induce LASV-specific anti-NP and anti-GPC immune 
responses (Table 1) [17]. 
As expected, LASV/JOS GPC-based experimental vaccines were protective against 
challenge with the homologous JOS strain or strains from the same clade but from different 
geographical areas [128]. While LASV/JOS represents the largest collection of LASV strains in 
West Africa, the most diverse LASV strains from clade I-III circulate in Nigeria [53, 56]. The ML29 
vaccine expressing both JOS-derived genes, NP and GPC, fully protected strain 13 guinea pigs 
and NHPs against LASV/JOS(IV) and LASV/803213(II) [125]. Taking into consideration the close 
phylogenetic relationship between clade IV and III, the ML29-induced protection against LASV 
strains from clade III is very likely.   
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LASV/JOS causes fatal disease mimicking human LF in strain 13 guinea pigs and NHP 
species, rhesus, cynomolgous, and African green monkeys, and in marmosets [122, 123, 126, 
195]. Infection of capuchin and squirrel monkeys resulted in mild disease. Strain 13 guinea pigs 
and cynomolgous monkeys are the most widely used “FDA-validated” LASV/JOS challenge 
models. Animal studies of Nigerian LASV strains are limited. The LASV/GA391 from clade III is 
lethal for Hartley guinea pigs [127].  The Nigerian prototypic strain 803213 from clade II causes 
LF-like fatal disease in strain 13 guinea pigs and marmosets. However, the prototypic strain 
LP/NIG69/H (clade I), which occupies the bottom of LASV phylogenetic tree, did not induce fatal 
disease in strain 13 guinea pigs, complicating the evaluation of efficacy of experimental LASV 
vaccines  [128]. There is no information on the sensitivity of NHPs to LASV/LP infection. 
Taking into consideration the distant genetic relationship between clades I and IV, there 
is a concern that LASV/JOS-based vaccines will not provide full protection against LASV/LP 
challenge. In this case, LASV/LP antigens (at least GPC) need to be included in the vaccine 
formulation. Both advanced vaccine candidates, rVSVΔG/LASV-GPC and ML29, have powerful 
reverse genetics tools capable of adding the expression of GPC from LASV/LP. Successful 
expression of two arenaviral glycoproteins including LASV GPC from clade I and IV was also 
reported in an alphavirus RNA replicon system [161, 175, 196]. The development and 
standardization of reliable challenge models for Nigerian strains of LASV is urgently needed to 
secure clinical development of successful LASV vaccine in West Africa.   
9. Vector Platform-based LASV vaccine candidates  
In contrast to EBOV and other emerging pathogens, which cause unpredictable 
outbreaks with limited numbers of human cases, LF is a common disease in West Africa. In 
emergency and non-emergency situations, regulatory agencies (the US Food and Drug 
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Administration, FDA; the European Medicines Agency, EMA) will require LASV vaccine efficacy 
trials in humans. Both agencies can act as Reference National Regulatory Authorities (NRAs) for 
the purposes of WHO pre-qualification, and/or assist other NRAs in their evaluation of the safety 
and effectiveness of the vaccine. Further, both NRAs will issue a Certificate of Pharmaceutical 
Product (CPP) upon which some countries will then use as the basis for their review of a vaccine 
candidate. In the US, the FDA encourages the path to Biological License Application (BLA) and 
licensure even if disease is not endemic in the US. Vaccine development in the US follows the 
same general path as other drugs intended for human use, and is evaluated during clinical 
development under an Investigational New Drug (IND). Sponsors of vaccines for diseases 
endemic in geographies outside the US have access to a variety of regulatory mechanisms of 
acceleration, such as “Fast Track” designation, and others that address unmet medical needs.  
In the EU, the EMA is responsible for the scientific evaluation of marketing applications, 
with the Committee for Medicinal Products for Human Use (CHMP) holding responsibility for 
human medicines, including vaccines. The EMA has a procedure (Article 58) that allows the 
agency to render an opinion in cooperation with the WHO for the evaluation of drugs intended 
for use outside the European Community. 
The history of the development and regulatory pathway of Candid 1, the first arenaviral 
vaccine (manufactured and licensed in Argentina) [197], can be a valuable guideline for LASV 
vaccine clinical development.  Candid 1 significantly reduced numbers of arenaviral HF cases 
from 3,500 to 30-50 per year. In the US, Candid 1 is still under IND status and it is not 
“approvable” due to missing records of passages at the early stages of attenuation. The 
redesigned, “rescue” of recombinant Candid 1 from cDNA clones provides hope that a version of 
Candid 1 will get FDA approval in the future [198].   
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Currently, two vaccine candidates, ML29 and rVSVΔG/LASV-GPC, have been considered 
for “accelerated” development [199], and the rVSV-based LASV vaccine is scheduled to be 
tested in a Phase I trial in 2017-2018 [166]. There is a solid rationale to assess safety and dose-
dependent immune responses (phase II) in volunteers in endemic and non-endemic areas 
before getting the national authorization for efficacy trials. Nigeria has the most developed 
medical infrastructure in Sub-Sahara Africa, and several clinical research centers are already 
involved in LASV international research programs [53, 157, 200]. Together with Guinea and 
other African countries, Nigeria is a member of African Vaccine Manufacturing Initiative, with a 
mission to promote the establishment of sustainable human vaccine manufacturing capacity in 
Africa.  
While the clinical development of LASV vaccines in Africa is feasible, several risk factors 
have to be taken into consideration and addressed. First, contract research organizations (CROs) 
managing all aspects of clinical development under “good clinical practices” are not well 
represented in West Africa. Family Health International (FHI360, www.fhi360.org) with regional 
medical research experience, including development of EBOV vaccines, can be considered as a 
potential partner for clinical trial-related operations. Second, to secure proper enrollment, a 
clear description of benefits and potential risks for healthy subjects needs to be provided. Third, 
the regulatory environment and the broad range of costs per patient (from $2,500-5,000 in 
Nigeria to $8,500 in Sierra Lone) is additional factor of uncertainty.  
In “first-in-human” safety trials, 18-55 years old subjects with a healthy immune system 
will be enrolled, with well-defined inclusion and exclusion criteria. There is a reasonable 
expectation that dose-dependent immunogenicity trials would be conducted in endemic areas, 
with the possible enrollment of healthy subjects previously exposed to LASV infection. Prior 
immunity will potentially affect vaccine-induced immunity, and will require sub-group analysis 
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to assess immunogenicity in naïve recipients receiving low and high doses of the vaccine. Safety 
and immunogenicity of LASV in HIV-1 positive subjects is a solid rationale for separate trials after 
the basic safety and immunogenicity profile of the vaccine in healthy individuals is defined.  
The “ideal” LASV vaccine has to be developed for the general population of West Africa 
including children from different age groups. Pediatric studies in the US and the EU are subject 
to special provisions of the clinical trial regulation, and a Pediatric Investigational Plan (PIP) 
would normally need to be developed and authorized. Currently, there is no clear regulatory 
pathway describing how to incorporate a PIP in LASV vaccine development. As such, a PIP 
should be prepared and discussed with the FDA and the EMA during the pre-IND and Scientific 
Advice meetings.  
One of the goals of the recently launched Coalition for Epidemic Preparedness 
Innovations (CEPI) is to optimize the approval process for vaccines against emerging infectious 
diseases, and make this process significantly shorter, transparent, and more effective [201-203]. 
There is a hope that the CEPI initiative will be a game changer, and will provide innovative tools 
to proactively develop and manufacture vaccines against epidemic infectious diseases. 
Accelerated clinical development of LASV vaccine is one of the CEPI priorities for the next five 
years.   
Conclusion 
LASV infection is a growing threat for the populations of West African countries and 
non-endemic areas. Recent evidence of LASV expansion suggests that all countries in the 
tropical wooded savanna areas between Nigeria and Senegal can be considered a LASV endemic 
zone. Improvement in molecular-based detection of LASV and species-identification of small 
mammals discovered new LASV-related species and new LASV natural hosts. Taking into 
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consideration the high genetic and biological diversity, the taxonomic status of LASV as a single 
species may be reevaluated in coming years.  
Our knowledge of how LASV interacts with susceptible cells has been significantly 
improved. Although sophisticatedly-glycosylated α-DG is the major LASV cellular receptor, some 
C-type lectins and TAM family proteins can also be involved in LASV entry in cells lacking 
functional α-DG (e.g., mature hepatocytes). The requirement of the intracellular receptor 
LAMP1 for LASV entry provided evidence of similarity with EBOV entry. Despite differences in 
morphology and vesicular trafficking, both viruses use glycoprotein GP1 sub-unit to initiate 
interactions with host receptors and the required intracellular receptor switch, to NPC1 (for 
EBOV) and to LAMP1 (for LASV) for cell entry. The surface of both viruses are heavily 
glycosylated to prevent interaction with specific antibodies, a common mechanism of immune 
control evasion. Intriguingly, the GP2 sub-unit of newly discovered reptilian arenaviruses are 
highly similar to those of EBOV suggesting a possible ancestor interaction between arena- and 
filoviruses.  
A NHP model continues to be the major source of our knowledge on LF pathogenesis. In 
this model, LASV strains from different endemic areas demonstrated a range of clinical 
manifestations from mild infections with low lethality to severe hemorrhagic fevers with fatal 
outcome, potentially mimicking differences in clinical forms of human LF. With obvious 
limitations, murine models can still be helpful to study certain steps of the acute disease (e.g., 
liver involvement), LF sequelae (e.g., sensorineural hearing deficiency), and immunogenicity of 
experimental LASV vaccines (vaccine potency). Some evidence of LASV-induced 
immunopathology observed in immunocompromised and chimeric mice seems to be associated 
with the inherent phenotype of LASV (and LCMV) in mice/rodents.  
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With improvements in virus and antibody detection, the negligible role of humoral 
responses in recovery and protection during the natural course of LASV infection was 
additionally documented.  Nevertheless, monoclonal antibodies specific for LASV GPC were 
successfully cloned from memory B cells of the survivors, and demonstrated therapeutic 
activities in a NHPs lethal challenge model. These antibodies can potentially be used alone or in 
combination with ribavirin for the treatment of LF patients at the time of hospital admission.  
A new generation of replication competent vaccines represents the most feasible 
approach to control LASV. At least two vaccine candidates, rVSVΔG/LASV-GPC and reassortant 
ML29, have demonstrated safety and efficacy in NHPs, and are well positioned for rapid clinical 
development. The new initiative, Coalition for Epidemic Preparedness Innovation (CEPI), has 
been recently established for proactive development of effective vaccine against epidemic 
infections. The CEPI included development of LASV vaccines in its 2017-2021 business plan, with 
the goal  to develop vaccines through phase II for further stockpiling for emergency use and/or 
phase III efficacy trials. In case of LASV, “emergency use” is permanent since this infection is 
endemic for West Africa. This suggests that once regulatory issues for CEPI vaccines are settled, 
the lead LASV vaccines will be tested in multicenter efficacy trials in major endemic areas of 
Nigeria and West African countries.  
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CHAPTER III 
ATTENUATED REPLICATION OF LASSA VIRUS VACCINE CANDIDATE ML29 IN STAT-1-/- MICE1 
1. Introduction
Lassa virus (LASV) is a highly prevalent arenavirus in West Africa, where it infects several 
hundred thousand individuals annually. This results in a large number of Lassa fever (LF) cases 
that are associated with high morbidity and mortality rates [80, 133]. The natural LASV reservoir 
is the rodent Mastomys natalensis, which is widely distributed throughout sub-Saharan Africa. 
The area where LASV is endemic covers large regions of West Africa [61] putting a population of 
up to 200 million people at risk for infection [60]. Furthermore, there is evidence that LASV 
endemic regions are expanding [62]. The high degree of LASV genetic diversity [53, 56] likely 
contributes to underestimates of its prevalence [65]. With the exception of Dengue fever, LF has 
the greatest estimated global burden among all viral hemorrhagic fevers (HFs) [59]. LF outbreaks 
are associated with morality rates as high as 60%, as documented during the 2015-2016 
outbreak in Nigeria [147]. The currently ongoing 2018 outbreak is the worst on record [205]. 
There is no FDA-approved LASV vaccine or therapeutic. Treatment options are limited to off-
label ribavirin with varying degrees of success. In 2017-2018, the WHO included LASV on the top 
priority pathogens list and issued a Target Product Profile (TPP) for LASV vaccine development 
[64, 206, 207].  
1 This chapter is adapted from work published in Pathogens, 2019, Volume 8, Issue 1 with the same title 
under a Creative Commons Attribution (CC BY) license [204]. 
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LASV belongs to the Old World (OW) group (former lymphocytic choriomeningitis virus, 
LCMV-LASV sero-complex) of the genus Mammarenavirus of the Arenaviridae family [45]. The 
LASV genome has two RNA segments that each encode two open reading frames in opposite 
polarities, separated by a structured intergenic region. The L RNA encodes for a large L protein, 
which functions as a RNA-dependent RNA polymerase (RdRp), and a RING finger protein Z, 
which comprises the matrix of virions. The S RNA encodes for a nucleoprotein (NP) which tightly 
associates with viral RNA and a glycoprotein precursor (GPC) that is processed into three 
subunits: a stable signal peptide, SSP; a receptor-binding GP1; and a transmembrane GP2 which 
mediates fusion with cell membranes. All three glycoprotein subunits associate to form club-
shaped features on the surface of pleomorphic viral particles, which vary in the diameter from 
50 to 300 nm. In addition to LASV, the OW group includes genetically related non-pathogenic 
viruses: Mopeia (MOPV), Morogoro (MORV), Gairo (GAIV) and Luna (LUNV) hosted by the same 
rodents [69-72]. The New World (NW) mammalian arenaviruses (former Tacaribe virus, TCRV, 
sero-complex) comprise viruses which circulate in Americas, and include the causative agents of 
South American HFs [208]. 
Reassortant studies using genetically-related mammalian arenaviruses with different 
pathogenic potential demonstrated that the L gene is responsible for high levels of virus 
replication in vivo, and is associated with acute disease in experimental animals [209, 210]. Co-
infection of cells with LASV and MOPV resulted in generation of MOPV/LASV reassortants [18, 
211]. One of the rationally selected clones, ML29, carrying the L RNA from MOPV and the S RNA 
from the Josiah strain of LASV (LASV/JOS), is a promising LASV vaccine candidate [17, 18, 199].  
While MOPV L RNA is the major driving force of ML29 attenuation, eighteen mutations 
incorporated in the ML29 genome during in vitro selection additionally seem to contribute to 
the attenuation of ML29 [17, 212]. Indeed, transcriptome profiling of human peripheral blood 
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mononuclear cells (hPBMC) exposed to LASV or ML29 exhibited distinct molecular signatures 
that can be useful biomarkers of pathogenicity and protection [16, 151]. Similar studies 
comparing MOPV and ML29 infected hPBMC revealed that gene expression patterns in mock 
and ML29 infected hPBMC clustered together and differed from the expression pattern 
observed in MOPV infected hPBMC [16].  
Recently, recombinant ML29 (rML29) was rescued from cDNA clones and demonstrated 
the same features as a biological ML29 (bML29) [213]. Reverse genetics provides a powerful tool 
for elucidation of the individual contributions of ML29-specific mutations to attenuation. 
However, the absence of a reliable small animal model for LASV pathogenicity is a major 
obstacle for the field. LASV, as well as other mammalian arenaviruses, stimulate antiviral 
immunity differently in natural rodent hosts and in humans and non-human primates, NHPs [15, 
123, 159]. While some pathogenic features of human LF can be observed in strain 13 guinea pigs 
[122, 124, 214], there is a poor correlation between clinical outcome of LF in humans and 
virulence of LASV in guinea pigs [121]. Results of LASV vaccination/challenge studies in strain 13 
guinea pigs are not reproducible in NHPs [15, 175, 183]. In addition, strain 13 guinea pigs are no 
longer commercially available and difficult to breed.  
Rodent models remain useful to study some mechanisms of LF pathogenesis and 
protective immune responses, and to provide valuable information during pre-clinical 
development of vaccine candidates [123, 215]. Previous research has documented that mice 
lacking a functional STAT1 pathway are highly susceptible to LASV infection, and develop fatal 
disease with some pathological features that mimic human LF [198]. Notably, human LASV 
isolates from fatal LF cases in Sierra Leone induced clinically similar fatal disease including high 
viral load in blood and visceral organs of STAT-1-/- mice after intraperitoneal inoculation (i.p.). In 
contrast, LASV isolated from a non-lethal human case induced disease with moderate mortality. 
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Surviving mice developed hearing loss that mimicked the sensorineural hearing loss (SNHL) 
commonly observed in LF patients during convalescence [216].   
In this study, we provided additional evidence of deep ML29 attenuation by modeling 
the  LASV infection protocol for STAT-/- mice as a means to assess the safety profile of ML29 
(bML29 or rML29) in comparison with MOPV. We also generated ML29 stocks enriched with 
interfering particles (IPs) produced by ML29-persisitently infected cells. The growing body of 
evidence indicates that, during natural infection, IPs are critically involved in the modulation of 
viral load, innate immune responses, disease outcome, and contribute to the evolutionary 
persistence of viruses [217-219]. An accumulation of IPs with genome deletions have been 
documented during the production of live-attenuated polio [220], influenza [221, 222] and 
measles [223-225] vaccines, and was associated with  modulating vaccine potency and 
immunostimulatory properties. Here, we demonstrated that STAT-/- mice are a susceptible 
model capable of discriminating between viruses with different levels of attenuation, MOPV and 
ML29. ML29 IPs were completely attenuated in these mice, enhancing immunogenic features of 
ML29. The broad cross-protection activity of ML29 IPs and their intrinsic adjuvant features can 
be potentially used for rational formulation of a pan-LASV ML29-based vaccine by developing 
vaccine manufacturing protocols to optimize the ratio between infectious ML29 and IPs.  
2. Results
2.1. Generation of interfering particles (IPs) by ML29-persisitently infected cells 
Arenavirus IPs can be generated at high multiplicity of infection (MOI) by serial infection 
of fresh tissue cultures with undiluted culture medium harvested from previous passages. 
Alternatively, initially infected cells can be subjected to serial passages. Both methods resulted 
in the accumulation of IPs. Earlier studies suggested a contribution of IPs in the establishment 
34 
and/or maintenance of LCMV persistent infection in vitro and in vivo, and in the inhibition of 
virus-induced immunopathology in mice [226-232]. The protocol previously applied for the 
generation of LASV IPs in cell cultures was used to establish ML29 persistent infection of Vero 
cells. In line with previous observations [233-235], passages of ML29-infected cells, either 
infected with bML29 or with rML29, resulted in the gradual decline of infectious particles 
released in culture medium. As seen in Figure 1, the infectious titers of ML29 released into the 
medium of persistently infected Vero cells (Vero/ML29) was reduced almost 100-fold after 10 
passages, and was under detectable levels after 15 passages. Vero/ML29 cells strongly 
interfered with replication of homologous (ML29) or genetically related LASV/JOS, LCMV, and 
MOPV and did not generate infectious plaques after super infection of Vero/ML29 with these 
viruses. Meanwhile, neither the replication of TCRV, a NW arenavirus, nor the non-related Ebola 
virus was affected in these cells. ML29 IPs released from persistently infected Vero/ML29 cells 
were able to suppress replication of homologous virus in a dose-dependent manner (Figure 1f). 
While the replication of ML29 or LASV was not detectable in ML29/Vero cells after 
passage 10, viral proteins were detected in these cells by immunofocus (IF) assay (Figure 1c). In 
contrast to infectious “plaques”, this assay detects cells expressing virus antigens stained by 
specific antibodies. With an increasing number of passages, ML29-infected cells lost their ability 
to produce plaques after homologous superinfection, but were strongly positive for ML29-
specific antigens as demonstrated by quantitated analyses (Figure 1c; Figure 6). Differences in 
the morphology of IF foci between naïve and Vero/ML29 cells after infection and superinfection 
with ML29, respectively, seems to be related to differences in the expression of NP and GP 
proteins in different passages of Vero/ML29. 
Viral RNA load in Vero/ML29 cells, as assessed by quantitative qRT-PCR targeting the NP 
gene, declined about 10 fold during the first five passages and persisted approximately at the 
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same levels during subsequent passages of Vero/ML29 (Figure 1b). Viral RNA load remained at a 
similar level through 50 passages (data not shown.) Our attempts to detect genomic RNA 
deletions, either in infected cells or in virions released from infected cells, using RT-PCR failed 
(not shown, see Discussion).   
2.2. MOPV and attenuated reassortant ML29 induce experimental disease with different clinical 
manifestations and outcome in STAT-1-/- mice 
In STAT1-/- mice, LASV infection resulted in experimental disease with the outcome 
depending on the pathogenic potential of the LASV isolate [216]. Based on these observations, 
we tested the attenuation of MOPV and ML29 in these mice. Using the LASV infection protocol, 
three groups of mice (n=9) were IP inoculated with MOPV, ML29 and ML29P50 (IPs produced by 
Vero/ML29, passage 50). MOPV infection resulted in poor grooming, lethargy and signs of 
dehydration starting around day 8-post infection. These symptoms aggravated, and the mice 
gradually lost weight, and experienced a drop in body temperature. All animals in this group met 
euthanasia criteria within 11-17 days following infection (Figure 2). In ML29 infected STAT1-/- 
mice, the symptoms started to improve at the late stage of the infection. Body temperature 
quickly recovered after day 10 and 33% of mice survived at day 21. No clinical signs were 
observed in the ML29P50 group. These mice gained weight at the end of the observation period 
and their temperature fluctuated within a normal range.  
As a control, wild type mice with an identical genetic background were i.p. inoculated 
with MOPV, ML29 and ML29P50. The mice were successfully infected with these viruses as was 
documented by detection of viral RNA in tested tissues (Figure 7). However, in the wild type 
mice, the replication of the viruses was well controlled and viral RNA was barely detectable at 
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day 21. As expected, infection did not induce clinical manifestations in any of the wild type study 
groups, and these mice gained weight at the end of the 21 days observation period. 
2.3. Replication of MOPV and ML29 in tissues of STAT- -/- mice: no viremia and infectious virus in 
tissues of ML29P50 infected mice 
High viremia, infectious titers, and viral RNA loads were associated with replication of 
MOPV in tissues of STAT-1-/- mice as assessed by infectious plaque assay and qRT-PCR (Figure 2). 
At the peak of clinical manifestation, day 7-10, viremia and viral load in the liver reached more 
than 1x107 PFU/ml or PFU/g, respectively. RNAscope in situ hybridization confirmed extensive 
liver infection with strong signals associated with hepatocytes and endothelial cells (Figure 3, 
arrowed). In contrast, replication of ML29 was more attenuated in STAT-1-/- mice. Viremia and 
viral load in the liver was 3-logs lower in these mice compared with MOPV infection, and only a 
few weakly-positive hepatocytes were seen in ML29-infected liver samples. In brain tissue, 
replication of infectious ML29 was transiently detected at early and late stages of infection. 
Replication of infectious ML29P50 in STAT-1-/- mice was below detectable levels in blood, liver, 
and brain. However, replication of ML29P50 was detected in tissues by viral RNA-based assays, 
qRT-PCR, and RNAscope in situ hybridization. As seen in Figure 2g-i, at early stage of the 
infection, relative levels of ML29P50 viral RNA in tissues were lower than MOPV and ML29 viral 
RNAs. ML29P50 was barely detectable in the tissues at late stage of the infection. This indicates 
that ML29P50 was well controlled, an observation that is in line with the absence of clinical 
manifestations. 
2.4. Host responses in mice infected with MOPV and ML29 
Cell-mediated immune responses in infected mice were assessed by ELISPOT using 
stimulation of spleen cells isolated on day 3, 7, and 21 after infection with peptide cocktails 
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derived from LASV/JOS GPC and MOPV GPC as previously described [165, 236]. At day 3, virus-
specific T cells secreting IFN-ɣ, IL-2, or both were barely detectable in all groups of mice (not 
shown). By day 7, in STAT-1-/- mice, comparable levels of IFN-ɣ-secreting cells (~ 0.4% of total 
spleen cells) were observed in spleens from ML29 and ML29P50 infected mice (Figure 4a). In 
wild type mice, ML29 and ML29P50 infection induced slightly lower T-cell responses. Notably, in 
wild type and STAT-1-/- mice infected either with ML29 or with ML29P50, similar levels of IFN-ɣ-
secreting cells were induced after stimulation with GPC cocktails derived from LASV or MOPV. 
Infection with MOPV induced comparatively diminished T cell responses in wild type and in 
STAT-1-/- mice, predominantly after stimulation with homologous MOPV GPC-derived peptides. 
After stimulation with GPC cocktails, spleen cells isolated from mice infected with ML29 and 
ML29P50, but not with MOPV, also secreted IL-2 cytokine, ~ 0.1% of total spleen cells. Cells 
secreting both cytokines were easily detectable at day 7 in ML29 and ML29P50 mice after 
stimulation with homologous antigens. In MOPV infected STAT-1-/- mice, this cells population 
was barely detectable.  
Survival of ML29P50-infected mice was clearly associated with strong cell-mediated 
responses. As seen in Figure 4, in spleens isolated from STAT-1-/- mice on day 21, cells secreting 
IFN-ɣ, IL2, or both were strongly upregulated after stimulation with GPC cocktails, > 0.3-0.6%. In 
wild type mice inoculated with ML29P50, these responses had declined by this time point. 
Interestingly enough, in both groups of mice infected with ML29P50 humoral responses were 
similar (Figure 4g). 
Measurement of pro-inflammatory cytokine expression in spleen of STAT-1-/- mice 
infected with MOPV revealed upregulation of IL-6 and IL-1β at early stages of the infection and 
rapid declined at later time points while TNF-α was down-regulated for all viruses except the 
early stages of MOPV and the late stage of ML29P50 (Figure 5, Figure 8).  Levels of IL-1β and IL-6 
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mRNA in spleens of the mice infected with ML29 and ML25P50 were upregulated at day 3 and 
day 7, respectively.  At the later time point, the infection had minimal if any effect on TNF-α and 
IL-1β expression in STAT-1-/- and control mice. In MOPV-infected wild type mice, IL-6 mRNA 
levels had similar kinetics with those in STAT-1-/- mice, with down-regulation in the liver and 
spleen tissues during the infection. 
3. Discussion
The first aim of this study was to determine if STAT-1-/- mice provide a reliable small 
animal model to assess level of attenuation of LASV-related arenaviruses. LASV and MOPV share 
a common reservoir, M. natalensis, found in Western and Southeastern regions of Africa [69, 70, 
237]. In Mozambique and Tanzania, areas where MOPV and MORV are prevalent, there is a 
marked absence of clinical cases of LF. Additionally, MOPV does not cause clinical signs in guinea 
pigs and NHPs [122]. These observations, combined with ability of MOPV to generate in vitro 
replication-competent reassortants with LASV [18], and to protect experimentally infected NHPs 
against fatal LF [73], suggests that MOPV is a “naturally-attenuated” genetic relative of LASV. 
Studies to assess virulence of human LASV isolates in NHPs are very limited [129]. LASV 
isolates from LF patients with different clinical outcome showed a weak correlation between 
severity of human disease and virulence in guinea pigs [121, 238]. Meanwhile, in STAT-1 -/- mice, 
outcome of the disease correlated with virulence of human LASV isolates. 4 out of 5 mice 
infected with a lethal isolate met euthanasia criteria between days 7 and 8, while mice infected 
with nonlethal LASV isolates developed chronic disease [198, 216]. In our experiments, MOPV 
infection of STAT-1-/- mice induced manifested disease that met euthanasia criteria 11-17 days 
post infection (Figure 2a). The delayed euthanasia time-point of 11-17 days versus 7-8 days, 
indicates some level of attenuation of MOPV infection in STAT-1-/- mice. However, high levels of 
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viremia and viral load in target tissues, comparable with those in animals infected with virulent 
LASV isolates [198, 216], and poor adaptive immune responses (Figure 4) resulted in aggravated 
disease. In contrast to MOPV, ML29 infection in STAT-1-/- mice was more attenuated, and 33% of 
animals survived in this group (Figure 2a). Compared to MOPV infected mice, ML29 infection 
notably resulted in more than a thousand-fold reduction in viremia and viral load in tissues by 
plaque assay (Figure 2d-f). Strong T cell responses contributed to viral control in this 
experimental group (Figure 4). It is well documented that strong T cell-mediated immunity 
correlates with protection and positive clinical outcomes in experimentally infected NHPs and LF 
patients [159, 169, 239, 240]. 
The second aim of this study was to assess the contribution of IPs generated by ML29-
persistently infected cells to the attenuation and modulation of immune responses. Similar to 
many other RNA viruses, mammalian arenaviruses can generate IPs during acute infection of 
cells at high MOI, or during persistent infection. The defective IPs: (i) are antigenically identical 
to parental viruses and contain the same structural proteins; (ii) preserve 5’ and 3’ terminal 
sequences of parental genome but have extensive internal deletions; (iii) can only replicate with 
help of standard virus; and (iv) strongly compete for replication machinery with the parental 
virus [178, 241-244]. Historically, arenavirus IPs were observed following in vitro infection at 
high MOI, and masked the cell-killing potential of standard viruses. Earlier studies suggested the 
contribution of IPs in the establishment and/or maintenance of LCMV persistent infection in 
vitro, and in inhibition of virus-induced immunopathology in mice [226-232]. Similarly, LASV IPs 
generated by persistently infected cells strongly interfered with replication of standard LASV in 
vitro, were attenuated in C3H mice, and partially protected mice against wild type LASV 
challenge [233, 235, 245, 246]. In contrast to IPs generated from VSV, Sendai, Sindbis, and other 
RNA viruses, arenavirus IPs are difficult to separate from standard virions [229]. The unique 
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ability of mammalian arenaviruses to incorporate host ribosomes and RNAs during the late stage 
of virus maturation [45] seems to be responsible for failure of density-based methods to purify 
arenavirus IPs. Nevertheless, LCMV defective IPs partially purified from culture medium of  
persistently infected cells lacked the S RNA segment [247], compared to LASV defective IPs 
where the L RNA segment was not detectable [234]. In line with these results, UV inactivation 
experiments confirmed “smaller” genomes for LCMV [228] and LASV defective IPs [234]. The 
LCMV L RNA segment was much less abundant and not detectable during the early stage of 
persistent infection. However, RNA deletions were not found among virus-specific RNA species 
in brain tissue of LCMV persistently infected mice. During the progression of persistence, an 
accumulation of terminally truncated RNA species was documented [248].  
In our experiments, we were able to demonstrate the basic features of ML29 IPs 
generated by persistently infected cells (gradual infectivity loss during passages, antigenic 
identity and persistence, GP/NP ratio fluctuation, interference with homologous and closely 
related viruses) (Figure 1, 6). However, we failed to detect genomic deletions among virus-
specific RNA species extracted from persistently infected cells or among viral RNA extracted 
from concentrated supernatants by RT-PCR methods using different sets of primers to amplify 
the genomic L and S RNA segments. By using qRT-PCR quantification of the LASV(ML29) NP 
gene, we demonstrated that S RNA copies rapidly declined during the first five cell culture 
passages of infected cells and the number of copies persisted at roughly same levels during 
passages 10-25 (Figure 1b). These levels remain relatively constant for all subsequent passages 
tested through passage 50 (not shown). In contrast to the permanent level of the S RNA 
replication and protein expression detected by IF assay (Figure 1D), the infectivity of particles 
produced by persistently infected cells dropped dramatically during the first 10 passages, was 
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below the threshold of detection by passage 15 (Figure 1a), and was not detectable at the final 
passage 50.  
The inability of ML29-persistently infected cells to generate infectious plaques after 
homologous superinfection with ML29, or infection with LASV/JOS or MOPV, can be partially 
explained by arenavirus Z-mediated “superinfection exclusion” [249]. However, the replication 
of the NW mammalian arenavirus TCRV was not affected in ML29/Vero cells (Figure 1f). A recent 
study documented the capability of LCMV, LASV and MACV mammalian arenaviruses to 
replicate and disseminate without the Z protein providing evidence that NP can play role as 
potential surrogate of the Z protein [250]. We assume that ML29 IPs-induced interference was 
unlikely to be related to Z protein. Nevertheless, the contribution of the Z protein to innate 
immune responses cannot be fully excluded. ML29 has Z protein derived from MOPV. 
Interestingly enough, Z protein of pathogenic arenaviruses (including LASV,) but not that of 
nonpathogenic viruses, including the MOPV Z, inhibit RIG-I-like receptor-dependent IFN type I 
production [251]. 
In this study, we failed to provide evidence that ML29 IPs produced by ML29/Vero cells 
are “classical” defective IPs and the nature of ML29 IP-based interference has to be further 
elucidated. Nevertheless, ML29 IPs seem to be very attractive for vaccine formulation and 
development. First, as seen in Figure 2a, ML29P50 generated by ML29/Vero cells, passage 50, 
were completely attenuated in STAT-1-/- mice. These particles were not detectable by plaque 
assay (test on infectivity) in blood and tissues of mice. However, the level of ML29P50 RNA 
replication was similar or only slightly reduced in comparison with “wild type” ML29 RNA 
replication (Figure 2g-i). Second, while ML29P50 and ML29 induced comparable T cell responses 
at day 7, at the late stage of the infection ML29P50 generated much stronger T cell immunity as 
assessed by IFN-ɣ/IL-2 ELISPOT in line with the strong immunomodulation potency of defective 
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IPs [252]. While mechanism of LASV protection can be dependent on the vaccine platform itself, 
as well as the animal challenge protocol, in the case of the ML29 vaccine, T cell immunity, but 
not antibody production, was associated with protection of NHPs [161]. Third, ML29 is the only 
vaccine with documented evidence of T cell mediated cross protection against Nigerian LASV 
strains from clade II, among currently available LASV vaccine candidates [125]. This is critical 
considering the Nigerian LASV strains from clade II are responsible for causing the current 
unprecedented LF outbreak. LASV genetic diversity is the greatest challenge for vaccine 
development. The formulation of ML29 with IPs will improve the breadth of the host’s immune 
responses [251] and further contribute to the development of a pan-LASV vaccine with full 
coverage meeting the WHO requirements [64]. 
4. Materials and Methods
4.1. Viruses and Cells 
Generation of MOPV An20410, LASV/Josiah, and MOP/LAS reassortant (ML29) LCMV 
(WE and ARM) stocks in Vero cells and plaque titration technique was previously described [17]. 
Freeze-dried Tacaribe virus (TCRV-11573, ATCC® VR-1272CAF™) was purchased from ATCC and 
the virus stock was prepared by low MOI passage in Vero cells. Infectious plaques for all viruses, 
except MOPV, were counted at 5 days after infection by treatment of infected cell monolayers 
under agarose overlay with 4% paraformaldehyde and staining with 1% crystal violet. For MOPV, 
neutral red stain staining was used for plaque development. Vero C1008 cells (Vero 76, clone E6, 
ATCC® CRL1586) were maintained in DMEM/F-12 supplemented with 10% fetal calf serum, 1X 
antibiotic-antimycotic (ThermoFisher), and 1X Glutamax (ThermoFisher). ML29 persistent 
infection in Vero cells was established by using a previously described protocol [233, 234]. In 
brief, after the initial infection of Vero cell monolayers with an MOI of 1.0, at weekly intervals, 
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cells were detached from cell tissue flasks by treatment with 0.05% trypsin-EDTA 
(ThermoFisher) and sub-cultured at a 1:10 ratio. Culture medium was changed at 3-4-day 
intervals. Samples of cells and/or culture medium were used for plaque titration, antigen 
detection assays (IF, Western) and for RNA isolation. To titrate ML29 IPs produced by 
persistently infected Vero/ML29 cells, monolayers of naïve Vero cells were pre-treated with 
dilutions of Vero/ML29 passage 5, 20 and 30 supernatants for 1 hour followed by infection with 
ML29 and detection of plaques as described above. LASV/JOS or EBOV plaque titrations were 
performed in BSL-4 facilities using maximum containment practices at the University of Texas 
Medical Branch with the assistance of Dr. Slobodan Paessler’s lab.  
4.2. Immunofocus assay 
Vero E6 cells or ML29 persistently infected cells (Vero/ML29) were plated at a density of 
2x104 cells/well in 96-welltissue culture plates. 24 hours later, cells were overlaid with 
methylcellulose media. Naïve or Vero/ML29 cells were infected with 0.1 MOI of ML29 for 1 hour 
prior to being overlaid with methylcellulose. After 3 days, the methylcellulose was removed and 
cells were then fixed with an acetone methanol mixture. Residual endogenous peroxidase was 
blocked by hydrogen peroxide and cells were incubated overnight in 10% FBS. After washing, 
cells were treated with either polyclonal monkey-anti-ML29 antibody (1:400), monoclonal 
mouse-anti-LASV/JOS-NP, 1:100 (GenScript, Piscataway, NJ) or polyclonal rabbit-anti-LASV-GP 
1:400 (IBT Bioservices, Rockville, MD) followed by HRP linked appropriate secondary antibody. 
TrueBlue Peroxidase Substrate (SeraCare, Milford, MA) was used for detection. Quantification of 
staining from high-quality images of scanned plates was performed using Adobe Photoshop to 
reduce background and threshold images followed by ImageJ counting of pixels.  
4.3. Animal protocols 
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4–5 week old female STAT-1-/- mice (129S6/SvEv-Stat1tm1Rds) and wild type controls 
(129SVE-F) were purchased from Taconic (Hudson, NY). During a 1-week acclimation, a 
temperature and identification transponder was implanted subcutaneously and the mice were 
transferred to ABSL-3 housing at the NIH Regional Biocontainment Laboratory on the University 
of Louisville campus.  For infection, 1x103 PFU of MOPV, ML29 or ML29P50 (quantitated as a 
qRT-PCR equivalent dose) was administered (i.p.) in 100 μL of PBS. Mice were monitored daily 
during 21 days and any animal with 25% weight loss was determined to have met the humane 
euthanasia criteria. Plasma samples from infected mice that had been euthanized were 
collected in EDTA tubes (BD). Tissue sample homogenates (10% w/v) were prepared with an 
Omni TH Tissue Homogenizer in DMEM/F12 followed with centrifugation at 4,500 x g for 20 
minutes. Clarified tissue homogenates were tested in the plaque assay described above. All 
animal protocols were approved by the University of Louisville Institutional Animal Care and Use 
Committee. 
4.4. qRT-PCR and RNAscope in situ hybridization 
Tissue samples were placed into 2 ml screw-top tubes with 1 ml TRIzol Reagent 
(ThermoFisher) and glass beads, processed in a bead homogenizer, and tissue homogenates 
were stored at -80°C until RNA isolation by phenol-chloroform extraction and ethanol 
precipitation. The qScript cDNA super mix (Quanta Biosciences) was used to make cDNA with an 
input of 1000 ng of RNA. qRT-PCR with TaqMan primers targeting the MOPV L gene, the LASV 
NP gene, IL-6, TNF-α, or IL-1β were used  with a 18S housekeeping probe on a StepOnePlus qRT-
PCR analyzer (Applied Biosystems). All IL-6, TNF-α, IL-1β and 18S primer/probe sets were 
commercially purchased through ThermoFisher Scientific through the Applied Biosystems 
division. Primer/probe set for MOPV amplified a region of the L segment (FWD 5’-
TCCTCAATTAGG CGTGTGAA-3’; REV 5’-TACACATCCTTGGGTCCTGA-3’; probe 6FAM-
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CCCTGTTCCCTCCAACTTGTTCTT TG-TAMRA). Primer/probe set for LASV (ML29) amplified the NP 
gene segment (FWD 5’-TCC AACATATTGCCACCATC-3’; REV 5’- GCT GAC TCA AAG TCA TCC CA-3’; 
probe 6FAM TGCCTTCACAGCTGCACCCA-TAMRA). The qRT-PCR reaction contained 5 μM of each 
primer and 2μM of probe for each primer/probe set, 5 µl of cDNA and TaqMan Fast Advanced 
Master Mix (ThermoFisher) in a final reaction volume of 20 μL. The reaction conditions were as 
follows: 50 °C for 2 min, 95 °C for 20 sec then 40 cycles alternating between 95 °C for 3 sec and 
60 °C for 30 sec. For RNAscope hybridization, fixed tissue sections were embedding in paraffin, 
cut on a Leica RM2125 RTS microtome, and mounted on glass slides. Custom designed target 
probes, preamplifier, amplifier, and label probe targeting MOPV L RNA were synthesized by 
Adanced Cell Diagnostics (Hayward, CA) and RNAscope assay was performed according to the 
manufacturer’s manual. Chromogenic detection was performed using DAB followed by 
counterstaining with hematoxylin. 
4.5. EISPOT and IgG ELISA 
Assessment of T cell responses in infected mice by the murine IFN-γ/IL-2 Double-Color 
Enzymatic ELISPOT (Cellular Technology Ltd., Cleveland, OH) has been recently described [236]. 
In brief, erythrocyte-free splenocytes were added to 96-well filter plates (Millipore, MSIPS4510) 
pre-coated with anti-mouse cytokine antibody in triplicate at a density of 4x105 cells/well. Cells 
were stimulated overnight at 37°C with cocktails of 10 µM LASV/JOS or MOPV GPC peptides 
(Mimotopes Ltd, Melbourne, Australia). Each cocktail contained 69 overlapping 20-mer 
peptides. As positive and negative controls, Conconavalin A (ThermoFisher) and CLT media alone 
was added to quality control wells. After stimulation, plates were developed according to the 
manufacturer’s protocol and cells secreting individual cytokines IFN-γ or IL-2 or both were 
counted using C.T.L. Ltd. Immunospot® S5 Micro-analyzer and Immunospot® V 4.0 software. 
Quality control analysis was provided by C.T.L. Ltd.  
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IgG ELISA was performed as previously described [165]. In brief, microtiter plates were 
coated with 5x106 PFU/well of sonicated virus suspension in carbonate buffer (Sigma) overnight. 
Plates were washed, blocked with 10% milk for 2 hours, washed again, and coated with dilutions 
of mouse serum for 1 hour. Plates were washed and secondary HRP linked rabbit-anti-mouse 
IgG (Sigma) was added at a 1:2,500 dilution for 1 hour. Plates were washed and SureBlue TMB 
peroxidase substrate (SeraCare) was added for 15 minutes before the addition of TMB Stop 
Solution (SeraCare). 
4.6. Statistics Analysis 
Results are reported as means ± SEM (n = 4–5). ANOVA with Bonferroni’s post hoc test 
(for parametric data) or Mann-Whitney Rank Sum test (for nonparametric data) was used for 
the determination of statistical significance among treatment groups, as appropriate. Statistical 
analysis (mean, SD, T-test) and graphics were performed using the GraphPad Prism version 7 for 
Windows package (GraphPad Software, LaJolla, CA). 
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Figures 
Figure 1. Vero cells persistently infected with ML29 interfere with replication of homologous 
and genetically-related arenaviruses. (a) Supernatants from a Vero cell line persistently infected 
with ML29 (Vero/ML29) were titrated for infectious virus by plaque assay at the indicated 
passages. (b) Total RNA was isolated from a Vero/ML29 cells at the indicated passages and was 
assayed using qRT-PCR with a LASV/JOS NP TaqMan probe. Copy number was determined by 
regression against a standard curve. (c) Immunofocus assay using polyclonal monkey-anti-ML29 
on uninfected Vero E6 cells (top left), Vero/ML29 passage 34 cells (top right), Vero E6 cells 
infected with a 0.1 MOI of ML29 for 3 days (bottom left), and Vero/ML29 passage 34 cells 
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superinfected with a 0.1 MOI of ML29 for 3 days (bottom right). (d) Naïve or persistently 
infected Vero/ML29 cells at different passages were used to titer MOPV, LCMV/WE, TCRV, ML29 
by plaque assay. (e) Plaque-forming activity of Vero/ML29 cells. ML29 (top left and top center), 
LCMV/ARM (top right), LAS/JOS (bottom left and bottom left center), and EBOV (bottom right 
center and bottom right) were used in a plaque assay on Vero E6 cell (top left, bottom left, and 
bottom right center) or the 25th passage of a Vero cell line persistently infected with ML29, 
Vero/ML29P25 (top center, top right, bottom center left, bottom right.) (f) Dose-dependent 
effects of IPs on replication of ML29. Vero E6 cells were pre-incubated for 1 hour with the 
indicated dilution of ML29 IPs produced by Vero/ML29 cells at passage 5, 20 or 30. The pre-
treated cells were then infected with standard ML29 and viral titer was determined by plaque 
assay. Percent inhibition is normalized to infectious titer determined on Vero E6 cells that were 
not pretreated. 
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Figure 2. Clinical manifestation and outcome of MOPV and ML29 infections in STAT-1 -/- mice. (a) 
Mice were infected (i.p.) with 1x103 PFU of MOPV An20410, ML29 (standard infectious virus) or 
with ML29P50 (IPs collected from culture medium of Vero/ML29P50 cells). ML29P50 IPs were 
quantified by MOPV L gene qRT-PCR and used in genome-equivalent dose, 1x103 PFU. (b) 
Weight and (c) Temperature of infected mice. (d) Viremia, (e) Infectious viral load in liver, and 
(f) brain of STAT-1-/- mice. (g-i) Viral RNA load assessed as relative expression of MOPV L gene by 
qRT-PCR in the indicated tissues at the time point indicated. DPI, days post infection. EC, 
endpoint criteria. 
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Figure 3. RNAscope in situ hybridization. Representative images at two different magnifications 
(100x and 400x) of RNAscope in situ hybridization (brown spots, arrowed) targeting the MOPV L 
gene in the liver and kidney of STAT1-/- mice. 
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Figure 4. Adaptive immune responses of STAT-1-/- mice. ELISPOT counts per 4x105 splenocytes 
from STAT-1-/- mice or wild type (WT) controls collected (a-c) 7 days post infection or (d-f) at 
endpoint criteria or 21 days post infection. Splenocytes were stimulated with LASV GPC or 
MOPV GPC-derived peptide cocktails for 24 hours. (a, d) IFN-γ-secreted cells, (b, e) IL-2-secreted 
cells, or (c, d) poly-functional IFN-γ/IL-2-secreting cells. (g) Antibody responses measured by IgG 
ELISA in the serum of STAT-1-/- mice or wild type controls collected at 21 days post infection or 
endpoint criteria. >, Too numerous to count. 
Figure 5. Cytokine responses of STAT-1-/- mice. (a) IL-6, (b) TNF-α, or (c) IL-1β expression in 
splenocytes of STAT-1-/- mice relative to mock infected by qRT-PCR. 
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Figure 6. Quantification of immunofocus staining using polyclonal moneky-anti-ML29 on the 
indicated cell lines (A) without additional treatment, or (B) 3 days following infection with a 0.1 
MOI of ML29. (C) Western blot of cell lysates from ML29, Vero/ML29P26, and Vero/ML29P46 
detected with polyclonal monkey-anti-ML29 antibody. (D-E) Quantification of immunofocus 
staining using (D) polyclonal rabbit-anti-LASV-GP 1:400 or (E) mouse-anti-LASV/Jos-NP 1:100 
antibodies. (F) The calculated ratio between staining quantified in (D) and (E). * p < 0.05, ** p < 
0.01, *** p<0.001. 
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Figure 7. (A) Survival of wild type 129S6 mice infected IP with 1x103 PFU of ML29, 1x103 PFU of 
MOPV, or a MOPV L gene qRT-PCR equivalent dose of supernatant from passage 50 Vero/ML29 
cells. Daily (B) weight and (C) temperature of mice from (A). (D-F) Relative expression of MOPV L 
gene by qRT-PCR in the (D) liver, (E) spleen, and (F) kidney of wild type 129S at the time points 
indicated post infection. 
Figure 8. qRT-PCR analysis showing IL-6 expression in the (A) liver and (B) spleen , (C) TNF-α in 
the spleen, or (D) IL-1β expression in the spleen of wild type 129S6 mice infected with the 
indicated viruses relative to mock infected at days 3, 7, and 21 post-infection. 
Supplemental Materials and Methods 
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Quantification of immunofocus staining from high-quality images of scanned plates was 
performed using Adobe Photoshop to reduce background and threshold images followed by 
ImageJ counting of pixels. Statistical significance was tested with a one-way ANOVA using 
GraphPad Prism version 7. 
For western blotting, a T-75 cell culture flask with a confluent monolayer of either Vero 
cells was infected with a 1 MOI of ML29 5 days prior, or Vero/ML29, was harvested in Tris-buffer 
containing 1.0% NP-40, protease inhibitors and 0.1% SDS. Protein content was standardized 
based on a pierce modified Lowry protein assay (ThermoFisher) denatured by boiling in 
Laemmli’s buffer and run on a 10% acrylamide gel at 120V for 1 hour. The proteins were 
transferred to a nitrocellulose membrane, blocked with 5% milk, and detected with a 1:1000 
dilution of polyclonal monkey-anti-ML29 antibody. 
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CHAPTER IV 
SAFETY AND IMMUNOGENICITY OF A DEFECTIVE INTERFERING PARTICLE ENHANCED LASSA 
VIRUS VACCINE CANDIDATE IN STAT-1-/- MICE, CBA MICE, AND GUINEA PIGS 
Introduction 
Defective interfering particle enhanced ML29 (ML29P50) is attenuated in STAT-1 -/- mice 
compared to standard ML29 preparations [204]. Additionally, ML29P50 elicits greater specific T-
cell mediated immunity than ML29 upon stimulation with both homologous peptides from Lassa 
virus (LASV) strain Josiah (LASV/Jos) glycoprotein precursor (GPC) and heterologous peptides 
from Mopeia virus (MOPV) [204]. 
Retinoic acid-inducible gene I (RIG-I), melanoma differentiation-associated antigen 5 
(MDA-5), and dsRNA-dependent protein kinase R (PKR) are intracellular receptors that recognize 
arenavirus RNA during replication and induce innate immunity through activation of Nuclear 
Factor Kappa B (NF-κB), Interferon Response Factor 3 (IRF-3), and Interferon Response Factor 7 
(IRF-7) [253-255]. Old world arenaviruses including LASV, MOPV, and Lymphocytic 
Choriomeningitis virus (LCMV) antagonize these responses through the exonuclease activity of 
viral nucleoprotein (NP), and by the binding of the matrix RING-finger protein (Z) to the cellular 
RNA receptors [256, 257]. IRF-3 and IRF-7 play an important role in generating interferon 
responses and  apoptosis in a STAT-1 dependent manner [258, 259]. IRF-3 also stimulates 
chemokine and cytokine production in a STAT-1 independent fashion [259]. NF-κB activation can 
stimulate pro-inflammatory cytokine signaling and is important in the induction of adaptive 
immunity [260]. However, it has been reported that even in the absence of IFN signaling, MOPV, 
and to a lesser extent LASV, are able to induce interferon stimulated genes (ISGs) [254], 
potentially through the actions of  NF-κB and IRF-3. Notably, the NP-inducible anti-IFN activities 
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of arenaviruses are common features of mammalian arenaviruses regardless of their pathogenic 
potential for humans [256, 261, 262].    
Defective interfering genomes (DIG) have been described for most RNA viruses [263]. 
Classically, DIGs contain large deletions while preserving sequences required for replication and 
packaging into virions to create defective interfering particles (DIPs) [263]. Because DIGs are 
shorter than full length viral genomes, it is thought that they more efficiently compete for 
replicative machinery, which is responsible for the observed interference [263]. However, other 
mechanisms of DIG interference, including modulation of antiviral apoptosis responses, has also 
been observed [264]. For many viruses, DIPs can regulate virulence while stimulating host 
immunity [263]. A key component of this regulation is the induction of interferon responses and 
pro-inflammatory cytokines by DIPs [252, 265-268]. The inflammatory regulation for many DIPs 
can be attributed to engagement of RIG-I and MDA-5 [269, 270]. Additionally, DIPs may play a 
role in enhancing antigen presentation [271], which makes them an attractive tool for vaccine 
enhancement. A vaccine enhanced with DIPs would presumably have enhanced capacity for 
induction of innate immunity and superior antigen presentation. Additionally, it has been 
speculated that the interfering activity of DIPs could be exploited as antivirals [272]. The 
antiviral activity of DIPs may enhance the post-exposure prophylaxis therapeutic window for 
vaccination. 
DIP production by LCMV is thought to play a key role in the establishment of persistence 
in the rodent host [232, 273]. In LCMV, it has also been shown that phosphorylation of the late-
gene motif PPXY may play a role in the regulation of DIP production [273]. A key difference in 
DIPs observed from ML29 compared to those of LCMV, is that LCMV DIPs tend to exert waxing 
and waning interference (observed by increases and decreases in the infectious particle 
production from chronically infected cells) [274], while ML29 DIPs are associated with complete 
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abrogation of infectious particle production shortly after establish of persistent infection (15 
passages of ML29-infected cells)  [204].  
The genetic diversity of LASV has been one of the greatest challenges to vaccine 
development [67]. Currently, LASV strains are split into 4-6 phylogenetic lineages, which 
circulate in Nigeria and different areas of West Africa [275]. Interference mediated by DIPs 
provides a very attractive approach to overcome these phylogenetic barriers and develop pan-
LASV preventive and therapeutic strategies.  
DIGs still require wild-type (full-length) viral genomes for replication, which complicates 
detection of DIGs. If the DIGs were truncations instead of internal deletions, conventional PCR 
or sequencing methods would not be useful for detecting them. The presence of wild-type 
genomes in DIP can mask the presence of ML29 DIGs. For the New World arenavirus Machupo 
(MACV), deletions were detected by analysis of chimeric reads from next generation sequencing 
of viral stocks with reduced pathogenicity [276]. However, the direct contribution of these 
chimeric sequences to the interference of pathogenicity is unknown. 
In our study, Northern blotting (NB) was used to detect truncated viral RNAs directly 
from ML29-persistently infected cell cultures. Additionally, a minigenome-like L-segment with 
significant or total deletion of the L-gene was used to test the hypothesis that synthetic DIPs, 
similar to those noted for influenza [277], could interfere with arenavirus replication.  
Another challenge to address concerning LASV vaccine development is the potential for 
adverse drug effects including sensorineural hearing loss. LASV associated sensorineural hearing 
loss, thought to be due to T-cell mediated autoimmunity during convalescence, is a leading 
cause of deafness in West Africa [278-280]. To some extent, the STAT-1-/- mouse model 
recapitulates the hearing loss observed following LASV infection in humans and was proposed as 
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a model to test hearing loss as a possible adverse reaction following vaccination [216]. We 
hypothesized that because ML29 is able to induce robust T-cell responses in STAT-1-/- mice 
[204], that if these T-cell responses cause cochlear damage following ML29 vaccination, it would 
cause detectable hearing loss in the mice.  Additionally, since T-cell responses were stronger in 
ML29P50 vaccinated mice [204], these mice would seem to be even more susceptible to post-
vaccination hearing loss.  
In this study, the highly susceptible CBA/J model, and a Hartley guinea pig model that 
more closely mimics human responses to LASV infection were used further assess the safety of 
ML29 and ML29P50. CBA/J mice intracranially (IC) infected with ML29 or ML29P50 were used to 
confirm the attenuated phenotype of ML29P50, [17, 165]. Hartley outbred guinea pigs (Cavia 
porcellus) are susceptible to infection with some strains from LASV clade IV (LF2384 strain 
without adaptation [281] and LASV/Jos with adaptation [282],) and Nigerian LASV strain from 
LASV clade III [127]. Additionally, while strain 13 guinea pigs infected with LASV tend to show 
signs of airway disease, LASV infection of Hartley guinea pigs causes disease more typical of that 
observed in humans [123, 282]. Hartley guinea pigs were used to screen for signs of viral 
hepatitis and renal disease following vaccination with ML29 and ML29P50. Additionally, this 
model was used to investigate the potential for heterologous protection from LCMV strain WE 
(LCMV-WE) following ML29 vaccination. 
Methods 
Establishment of Vero cells persistently infected with ML29 and assessment of heterologous 
interference of persistently infected cells  
A persistently-infected subline of Vero cells was established as previously described 
[204]. In brief, Vero cells were initially infected with ML29 at a 0.01 multiplicity of infection 
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(MOI), and subjected to serial passages passaged normally every 7 to 10 days. Cell culture 
medium (ThermoFisher #11330032 supplemented with 1X antibiotic antimycotic #15240062, 
1Xglutamax #35050061, and 10% FBS #10438026,) was removed and cell monolayers were 
washed with PBS. Cells were detached from tissue flasks with a short treatment (5-10 minutes) 
with 0.05% Trypsin-EDTA (ThermoFisher #25300120), suspended in fresh culture medium, 
counted and plated in new tissue flasks  at a 1:10 to 1:5 ratio as previously described [204]. A 
naming scheme of “VeroML29PX” was employed to refer to the passaged cells with “X” being 
replaced with the passage number. VeroML29P25 and VeroML29P49 were cryopreserved at a 
density of 1x107 viable cells per 1 ml of cell culture media containing 5% DMSO (VWR #97063-
136). Cells were recovered and passaged several times before VeroML29P28 and VeroML29P53 
were plated at a density of 4x105 cells per well in 6-well tissue culture treated plates. After 
passage 15, persistently-infected cells failed to generate infectious “plaques” after infection 
with ML29 and the genetically-related viruses, LASV and LCMV [204]. To further assess the 
mechanisms of heterologous interference, VeroML28P28 and –P53 cells were infected with 
3.4x104 foci forming units (FFU) of tri-segmented Lymphocytic Choriomeningitis Virus strain 
Armstrong (LCMV-Arm) expressing green fluorescent protein (GFP) from both the nucleoprotein 
(NP) and glycoprotein precursor (GPC) loci from alternate S-segments, r3LCMV-Arm-GFP [283]. 
At 24 and 48 hours post-infection (HPI) images were captured with a BZ-X800 fluorescent 
microscope (Keyence, Itasca, IL, USA) with a 488 nm filter using 40% excitation light, 1/8.5s 
exposure, and a 4X lens in high sensitivity mode from the center of the well. The images were 
then compiled in Adobe Photoshop (Adobe Inc., San Jose, CA, USA) and the brightness and 
contrast were uniformly enhanced for visualization (brightness setting 56, contrast 88.) 
Northern Blotting 
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Vero cells were plated on 6 well tissue culture plates at a density of 4x105 cells per well 
and allowed to sit overnight prior to infection with 0.001 MOI of ML29, LASV/Jos (in the BSL-4 
facility at UTMB, Galveston), or MOPV strain AN20410 in 200 µL of 2% FBS cell culture media. 
Infection was allowed to occur on a rocking plate in a 37°C, 5 %CO2 incubator. After infection, 
the virus inoculum was aspirated and replaced with 2 ml of 2% FBS cell culture medium. At the 
indicated times, the cell supernatants were aspirated, and 1 ml of TRIzol (ThermoFisher 
#15596018) was pipetted over the cells 5-10 times before being transferred to a microfuge tube. 
Wells harvested before the end of the experiment were washed three times with 10% FBS in 
PBS to quench the phenol. RNA was isolated from the TRIzol with 1-bromo-3-chloropropane 
(Millipore Sigma #B9673) according to the manufacturer’s directions and stored in 30 µl of 
FORMAzol (Molecular Research Center, Inc., #FO 121). 
A 1.2% agarose gel containing 1X MOPS buffer and 6.6% (w/v) formaldehyde was made 
using DEPC water. Five µg of each RNA sample was mixed with 3.5 µl of 37% (w/v) formalin, 2 µl 
10X MOPS buffer, and 2 μg of ethidium bromide in a total volume of 20 µl FORMAzol prior to 
incubation for 15 minutes at 65°C. After rapid cooling, samples were mixed with loading buffer 
and run for 3 hours at 80V. The gel was then washed with two changes of DEPC water, followed 
by 10 mM sodium phosphate for 10 minutes each on an orbital shaker. The gel was then blotted 
onto a nylon membrane by upward capillary transfer, and UV cross-linked. Templates for probe 
generation were PCR amplified from ML29 L segment (for ML29 and MOPV detection) using 
forward (GATGT CAACA GATGA TAAGT CAGGC TTTAA AG) and reverse (CACCG GGGAT CCTAG 
GCATT G) primers, ML29 S segment (for ML29 detection) with forward (GGCCT TTCTG TTCTG 
ATCAC CTTTG A) and reverse (CGCAC AGTGG ATCCT AGGCT ATTGG) primers, or LASV L segment 
with forward (TCAGG GACTG TAGGG TGGGG GT) and reverse (ATGGG AAACA AGCAA GCCAA 
AGC) primers. Phosophorus-32 labeled ribonucleotides were used to generate probes from the 
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PCR amplified DNA, and the radioactive probes were hybridized to the nylon membrane. The 
membrane was washed, and exposed to film for 6 hours to develop. 
Quantification of virus stocks from the supernatant of VeroML29P50 cells 
Supernatants from VeroML29P50, referred to here as ML29P50, were quantified based 
on quantitative reverse transcriptase PCR (qRT-PCR) as described previously [204]. Briefly, RNA 
from ML29 and ML29P50 viral stocks was extracted in TRIzol LS (ThermoFisher #1026028) and 
reverse transcribed with qScript cDNA SuperMix (QuantaBio #95048, Beverly, MA, USA), prior to 
qPCR on a StepOnePlus analyzer (Applied Biosystems) using TaqMan Fast Advanced Master Mix 
(Thermo Fisher #4444965). Custom primers specific for the ML29 NP gene (FWD 5′-TCCAA 
CATAT TGCCA CCATC-3′; REV 5′- GCTGA CTCAA AGTCA TCCCA-3′; probe 6FAM TGCCT TCACA 
GCTGC ACCCA -TAMRA (ThermoFisher) along with a Eukaryotic 18S rRNA endogenous control 
(VIC/TAMARA) (ThermoFisher #431093E) were used. Dilutions of ML29 were used to make a 
standard curve based on the assumption that one copy of viral RNA detected correlates with 
one PFU of infectious virus. The number of ML29P50 copies per volume were plotted on this 
curve to determine the equivalent concentration of virus in the stock. 
Transfection of cells with minigenome (MG) constructs derived from the LCMV L RNA 
Arenavirus MGs provide valuable tools to study mechanisms of replication and 
transcription in vitro [181]. Most arenavirus MG systems are based on the S RNA sequences, and 
include minimal cis- (5’ and 3’ untranslated regions [UTRs] and the intergenic region [IGR]), and 
trans- (NP and L protein) elements required for replication/transcription. To study defective 
genomes derived from arenavirus L RNA, we designed MG system based on LCMV L RNA. In 
brief, the full length L-Segment of LCMV-Arm was replaced with a GFP gene, and named 
LCMV#1074. A similar construct was also made, except 198 nucleotides of the N-terminus 
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coding region of L was left intact, followed by a P2A linker, and a gene encoding for the 
fluorescent reporter ZsGreen, called LCMV#1076. These constructs were tested in the previously 
described LCMV rescue system [284, 285]. Briefly, BHK-21 cells were plated in 6 well tissue 
culture treated plates and allowed to rest for one day, at which point they were about 85% 
confluent. They were then transfected with the LCMV#1074 or LCMV#1076 constructs, using the 
Lipofectamine 2000 system (ThermoFisher #11668030) along with pCAGGs expression vectors 
coding for the LCMV L-RdRP protein and the LCMV nucleoprotein NP [193, 286]. In our 
experiments, BHK-21 cells were also transfected with LCMV#1074 or LCMV#1076 as described 
above, but without the trans-acting factors required for rescue. These cells were then infected 
with a 0.1 or 0.5 MOI of LCMV-Arm one-day post transfection to provide “helper” virus for L and 
NP production. The supernatant of these cultures was collected two days following transfection 
and titered on BHK-21 cells with detection of focus forming units (FFU) using anti-LCMV NP 
antibody VL-4 (BioXcell West Lebanon, NH, USA) conjugated to a 488 nm fluorescent dye using 
an antibody labeling kit (ThermoFisher #53024). 
In vivo CBA/J and STAT-1-/- mouse experiments 
Four week old female CBA/J were purchased from The Jackson Laboratory (Bar Harbor, 
ME, USA). Fifteen mice were randomly assigned to each group (n = 15) and allowed to acclimate 
for one week. Following acclimation, mice were inoculated IC with 103 PFU of ML29, the qRT-
PCR equivalent dose of ML29P50 (approximately a 1 to 20 dilution of the stock), or sterile PBS 
for mock treatment in a total volume of 10 µl. Mice were observed daily for up to two weeks for 
survival, weight, and clinical score based on a composite of grooming, adjusted grimace scale, 
activity and neurological manifestations, as previously described [44].  
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Four-to-five week-old female STAT-1-/- mice (129S6/SvEv-Stat1tm1Rds) were ordered 
from Taconic (Hudson, NY, USA). During a 1-week acclimation, mice were randomized into 
groups of 12 for ML29 and MOPV or 6 for ML29P50 or mock treatment. Prior to treatment, the 
mice were transferred to ABSL-3 housing at the NIH Regional Biocontainment Laboratory on the 
University of Louisville campus. At day 0, mice were inoculated via the intraperitoneal route (IP) 
with 103 PFU of ML29, the qRT-PCR equivalent dose of ML29P50 (approximately a 1 to 20 
dilution of the stock), MOPV, or sterile PBS for mock in a total volume of 100 µl. Mice were 
observed daily for up to 62 days for survival, weight, and clinical score. Hearing tests were 
conducted by acoustic startle with a SR-Lab startle response system (San Diego Instruments, San 
Diego, CA, USA) as previously described [216]. Supportive care of 1 ml of warmed 0.9% NaCl 
given subcutaneously (SC), access to sterile water soaked mouse chow on the cage floor, and 
DietGel  76A (Clear H2O, Portland, ME, USA) were provided to all mice in the study during 7-12 
DPI. After 12 DPI, supportive measures were discontinued for mock and ML29P50 groups based 
on veterinary advice, while mice in ML29 and MOPV groups received either 1 ml (13-15 DPI) or 2 
ml (16-18 DPI) of Lactated Ringers’ Solution given SC. Additionally, during 13-18 DPI, ML29 and 
MOPV groups received DietGel 76A, sterile 5% dextrose soaked mouse chow on the cage floor, 
and were housed with their cages placed half on a 42°C heating pad for thermal support. 
In vivo Hartley outbred guinea pig experiments 
Female Hartley outbred guinea pigs were ordered from Charles River (Willmington, MA, 
USA) with a requested weight of 250-300 grams. Upon arrival, all animals were randomized to 
study groups and allowed to acclimate for one week.  
For vaccination and heterologous challenge, 3 animals were assigned to each group (n = 
3) and transferred to ABSL-3 housing. Animals in the ML29 group received a single dose of 103 
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PFU of ML29 SC while mock vaccinated animals received PBS vehicle. Twenty-eight days 
following vaccination, animals were challenged with 103 PFU of the viscerotropic LCMV strain 
WE (LCMV-WE). 
Guinea pigs were vaccinated with 103 PFU of ML29 or a qRT-PCR determined equivalent 
dose of ML29P50. At 3, 7, and 14 DPI, four animals from each group were euthanized and blood 
was collected into K2EDTA tubes for peripheral blood mononuclear cell (PBMC) isolation. PBMCs 
from whole blood were isolated with SepMate50 tubes containing Lymphoprep (STEMCELL 
Technologies Inc., Cambridge, MA, USA) and washed twice in RPMI 1640 (ThermoFisher 
#11875093) supplemented with 1X antibiotic-antimycotic, 1X GlutaMax, 10% FBS, and 55 µM 2-
Mercaptoethanol (ThermoFisher #21985023). Washed cells were used for ELISpot analysis as 
previously described [287]. Guinea pig IFN-γ capture and biotinylated detection antibodies were 
a generous gift from Professor Hubert Schäfer (Robert Koch Institute, Berlin, Germany). Peptide 
cocktails containing a mixture of LASV strain Josiah glycoprotein precursor epitopes at a final 
concentration of 10 µM were used for specific stimulation. Spots were read and quantified on a 
S5 UV ELISpot reader using BioSpot and ImmunoSpot software (Cellular Technology Limited, 
Cleveland, OH, US). 
Blood collected in lithium-heparin microtiter tubes with a gel separator was spun at 
6,000 x g for 90 seconds. Plasma was separated and 100 µl was loaded onto a Basic Metabolic 
Panel Plus reagent disk, and run on a Piccolo Xpress analyzer (Abaxis, Union City, CA, US). A 
group of 3 unvaccinated guinea pigs challenged with 10 PFU of LCMV-WE provided blood for 
comparison. Samples from mock vaccinated animals were pooled from 11 total blood draws 
(separated by at least a week) from 6 different guinea pigs and the exact same 11 data points 
are presented as a comparison basis to both day 7 and 14 samples. 
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Results 
 VeroML29P53 cells interfere with replication of r3LCMV-Arm-GFP/GFP 
We have previously documented that persistently infected VeroML29P15+ cells lost 
their ability to produce infectious ML29 “plaques” under agarose overlay [204]. Notably, this 
interference was also associated with particles generated into culture medium of persistently 
infected cells. The homologous interference is one of the major features of DIPs. Additionally, 
the ML29-persisitently infected cells do not produce plaques when superinfected with 
genetically closely-related arenaviruses, LASV, MOPV, and LCMV. LASV and MOPV are parental 
viruses used to generate infectious reassortant ML29, one of the most promising LASV vaccine 
candidates [18]. ML29 contains the MOPV L-segment encoding the L and Z proteins, and the 
LASV/Jos S-segment encoding GPC and NP [18]. In mini-genome systems, the NPs and L proteins 
of LASV and MOPV were exchanged without loss of function [288]. Meanwhile, the LCMV L 
protein required homologous NP for activity [288], and co-infection of cells with LASV and LCMV 
failed to generate infectious reassortants (Lukashevich, unpublished). To investigate 
heterologous interference of VeroML29PX cells further, these cells were infected with tri-
segmented LCMV-Arm (r3LCMV-Arm-GFP/GFP). In this system, the level of replication and/or 
interference can be observed based on the inhibition of expression of the GFP reporter gene. As 
seen in Figure 9, in wild-type Vero cells, replication of r3LCMV-Arm-GFP/GFP resulted in strong 
expression of reporter gene in time-dependent manner. In contrast, in VeroML29P28 and 
VeroML29P53 cells, expression of the reporter gene was heavily suppressed, and only a few cells 
were GFP-positive in the VeroML29P53 infection. These results confirm our previous 
observation  that VeroML29PX cells interfere with replication of LCMV [1], and this interference 
can be measured either with classical infectious plaque assay, or by the expression of a reporter 
gene cloned/expressed in NP or GPC open-reading frames as in r3LCMV-Arm-GFP/GFP.  
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Sub-genomic RNA species in VeroML29PX cells 
Generation of deleted genomes during accumulation of DIPs (or interference activities 
in persistently-infected cells) is another major biological feature of DIPs [263]. Historically, 
sedimentation patterns in sucrose gradients of RNA isolated from interfering particles produced 
by LASV-persistently infected Vero revealed heavy deletions in the 28-31S sedimentations 
classes containing 28S host ribosomal RNAs and LASV L RNA species [234]. High resistance of 
interference activity of LASV DI genome to UV-inactivation also suggested genomic deletions 
[49]. Here, we applied NB analysis to detect RNA deletions associated with L-segment of DIGs 
from ML29 infected cells using an L RNA-derived radioactive probe. NB analysis allows native 
viral RNA detection without any potential PCR biased enhancement of “helper” genomes in the 
initial RNA samples. For NB analysis, three types of RNA samples were used: (i) RNA from cells 
infected with ML29 at low MOI (acute infection control); (ii) RNA from LASV- and MOPV-infected 
cells (low MOI); and (iii) RNA from ML29-persisitently-infected cells, VeroML29P28 and –P53. As 
expected, in cells infected with LASV and MOPV at low MOI, the predominant RNA band was the 
L RNA migrated in the gel with predicted molecular mass, ~ 7.2 kb. In ML29-infected cells (at low 
MOI), in addition to the high-molecular RNA species migrating at the position of L RNA, several 
smaller RNA species were detected with the L RNA-derived probe. The predominant species 
gradually accumulated during 2-4 days after infection and migrated as heterogeneous bands in 
the area of ~ 1.5 kb (Figure 10a). The low/undetectable (by plaque assay) level of ML29 
replication in persistently-infected cells reasonably generated a weak signal in our NB analysis. 
Nevertheless, a full-length L RNA can be detected in VeroML29P28 and –P53 cells. In 
VeroML29P53 cells, in addition to L RNA, two additional RNA bands were detected with the L 
RNA probe. The predominant band migrated as an RNA species with a length of ~ 3kb. In 
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addition, a tiny band migrated in the gel slightly slower than 1.5 kb RNA species can be also 
faintly detected.  
MGs derived from the LCMV L RNA failed to interfere with replication of infectious homologous 
virus  
Two artificial constructs of the LCMV L-Segment with fluorescent reporter replacement 
of the complete L-gene (LCMV#1074, Figure 11a top) or all but 198 Bp of the L-gene 
(LCMV#1076, Figure 11a bottom) were designed to test whether deletions in the L gene would 
result in successful competition (interference) with the replication of wild-type LCMV. Both of 
the constructs were replicated by the LCMV rescue system, and produced their respective 
fluorescent reporters (Figure 11b, left two panels, LCMV#1074 top, LCMV#1076 bottom). 
Additionally, LCMV-Arm infection was sufficient to provide the necessary trans-acting factors for 
replication, as seen by the fluorescent reporter produced from infection with 0.1 MOI (Fig 11b, 
center panels) or 0.5 MOI (Fig 11b, right panels) of LCMV-Arm. However, similar viral titers were 
isolated from the supernatants of cells transfected with LCMV#1074, LCMV#1076, or an 
irrelevant vector driving GFP production, at one day post LCMV infection (Figure 11c). This 
suggests that these constructs are insufficient to cause interference with in vitro viral 
replication. 
ML29P50 is attenuated in two mouse models 
One of the possible mechanisms of DIP-associated interference can be induction of 
innate (e.g., by RIG-I-dependent pathways triggered by pathogenic RNA species) and acquired 
immunity. Indeed, potent immunogenic features of DIPs are well documented for several RNA 
viruses and seems to contribute to vaccine efficacy [272]. Taking into consideration detection of 
substantial amount of L-derived RNA species in ML29 generated at low and high MOI (in 
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persistently-infected ML29 cells) we used two small animal models CBA/J mice and STAT-1-/- 
mice to test attenuation of ML29 and possible contribution of interfering particles. CBA/J mice 
are susceptible to both LASV and ML29 IC challenge [17, 165]. The CBA/J IC challenge model was 
also used to test the attenuation of ML29 enriched with DIPs, ML29P50. 
 All mice challenged with ML29 succumbed to infection at 7DPI, while all mice receiving 
ML29P50 survived two weeks following challenge (Figure 12a). Additionally, ML29P50 challenge 
mice did not show weight loss or the clinical manifestations caused by ML29 challenge at 6-7 
DPI. Viral loads in brain tissue measured by qRT-PCR at 7 DPI was undetectable for ML29P50 
challenged mice (data not shown). 
Mice deficient for STAT-1 do not respond to either type I or type II interferon and are 
therefore extremely susceptible to viral infection [289]. Likewise, STAT-1-/- mice are susceptible 
to LASV infection [198]. These mice can be also used to distinguish between lethal and non-
lethal human isolates of LASV. In addition STAT-1-/- mice surviving LASV infection show 
sensorineural hearing loss similar to that observed in human LASV survivors [216].  STAT-1 -/- 
mice are also susceptible to infection caused by ML29 and MOPV [204]. Because supportive 
measures are commonly used for human Lassa fever (LF) patients [290], we attempted to use 
supportive measures to increase the survival of STAT-1-/- mice following ML29 vaccination to 
examine the potential of the vaccine to cause sensorineural hearing loss. Supportive measures 
including fluid administration, caloric support, and temperature support during hypothermia for 
mice infected with ML29 or MOPV. While the efforts were largely unsuccessful with 1/12 ML29 
and 3/12 MOPV mice surviving (Figure 12d), survivors did not show weight loss (Figure 12e) or 
clinical manifestations (Figure 12f) that lasted more than 3 weeks following infection. This 
allowed for hearing tests by audible startle to check for signs of sensorineural hearing loss. No 
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hearing loss was observed in ML29, ML29P50, or MOPV mice at 62 DPI (Figure 12g-i) under the 
same conditions used to detect LASV associated hearing loss [216]. 
ML29 induces LASV-specific T cell responses in Hartley outbred guinea pigs 
Mice provide useful tools to study arenaviruses. However, mice cannot mimic the 
pathogenesis of the human diseases caused by these viruses. Guinea pigs with different genetic 
backgrounds are a more appropriate model for the study of LASV-induced pathogenesis and 
mechanisms of the protection. Hartley outbred guinea pigs are susceptible to infection with 
LCMV-WE with a LD50 less than 10 PFU, and display similar disease to those infected with LASV 
[209, 291, 292]. Hartley guinea pigs were used to study the anticipated cross-protection induced 
by ML29. The rationale of this study was based on the protection of Rhesus macaques 
vaccinated with ML29 against fatal LF-like disease caused by LCMV-WE [161]. As seen in Figure 
13a, at day 10, LCMV-WE also killed all Hartley guinea pigs infected with LCMV-WE. While 
vaccination with ML29 did not protect against fatal disease caused by LCMV-WE, we still 
observed a substantial delay in time of death for vaccinated animals. Furthermore, ML29 
vaccinated guinea pigs displayed LASV GPC specific T cell responses at 14 days following 
vaccination (Figure 13b). Their responses were measured in IFN-γ ELISPOT after stimulation of 
PBMC cells with peptide cocktails derived from LASV/Jos GPC, as previously described [204].  
Guinea pigs are also commonly used animals for pre-clinical toxicological studies to 
assess safety of biologics (vaccines and therapeutics). Neither ML29 nor ML29P50 treated 
animals had hematological signs of renal disease (Figure 13c-f) or viral hepatitis (Figure 13g-j) 
commonly seen in LF patients. However, LCMV-WE induced signs of renal disease observed in 
guinea pigs meeting endpoint criteria (EC) including elevated glucose, blood urea nitrogen, 
amylase, and decreased calcium (Figure 13c-f). LCMV-WE also induced viral hepatitis observed 
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by increased Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) and 
decreased albumin in EC guinea pigs. Interestingly, albumin was also significantly decreased at 
7DPI and there was a non-significant trend towards increased Gamma-Glutamyl Transferase at 
this time. 
Discussion 
Previously we documented that Vero cell persistently infected with ML29 after passage 
15 (VeroML29P15) did not generate infectious plaques under agarose overlay, a standard assay 
to quantitate replication-competent (infectious) viruses. In addition, these cells did not form 
plaques after super-infection with closely-related viruses, MOPV and LASV, and LCMV. While 
interference between ML29, MOPV, and LASV was highly expected, experiments in MG systems 
indicated that LCMV L protein requires specific (homologous) NP for MG function [288]. This 
finding is in line with the observed failure to generate live reassortants in cells co-infected with 
LCMV and LASV (Lukashevich, unpublished). To investigate further the heterologous 
interference of VeroML29P cells, we used tri-segmented LCMV expressing the GFP reporter 
gene, r3LCMV-Arm-GFP/GFP. In agreement with our infectious plaque assay results, ML29P28 
and ML29P53 cells interfered with replication of r3LCMV-Arm-GFP/GFP since the expression of 
the GFP reporter following infection with r3LCMV-Arm-GFP/GFP was significantly reduced. 
Greater interfering activity was seen in the VeroML29P53 cells, which tended to have 
approximately a 10- to 100-fold reduction in the number of GFP-positive cells infected at both 
24 and 48 hours. In VeroML29P28 cells, the total number of infected cells was more similar to 
that observed in standard Vero cells, however there was diminished average expression of the 
GFP in each infected cell. This is consistent with the observation that there is less viral protein 
(particularly GPC and NP) detected per cell by immunofocus assay in ML29P34 cells compared to 
cells with primary ML29 infection [204]. 
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Interestingly enough, in NB analysis with an L RNA-derived probe we observed 
numerous small RNA species with a size ranging from about 1 kBp to 4 kBp along with the 
expected viral genome and L mRNA. These L RNA-derived small RNA species were predominant 
in ML29-acutely infected cells. Notably, the S RNA-derived probe detected RNA species with 
expected size (viral S RNA and mRNA for NP). While the detection of small L RNA-derived species 
in ML29-infected cells infected at low MOI was a surprising finding, these small RNA species can 
contribute to enhanced immunogenicity of ML29. Small viral RNAs can be potent activators of 
RIG-I, MDA-5 or PKR [253]. We are assuming that part of the mechanism of advanced 
attenuation and/or immunogenicity of ML29 compared to MOPV is these small RNA species 
causing the activation of antiviral innate immunity at very early stages of the infection. This is 
very crucial to viral control and building potent acquired immune responses at latter stages of 
the infection. It has been documented that the L and NP genes from LASV and MOPV are 
interchangeable in a MG system [288]. However, LCMV L is not functional with LASV nor MOPV 
NP, although both LASV and MOPV L support MG replication with LCMV NP [288]. Importantly, 
most previously described arenavirus MG systems contained the cis-acting elements from the 
viral S RNAsegments [181, 288]. In these MG systems, NPs and L proteins of LASV and MOPV 
could be exchanged without loss of function. Still, the MOPV MG was about 3-fold less active 
than the LASV MG, irrespective of NP and L origin. This means that cis-acting elements (e.g., 
MOPV 3’UTR) contribute to MG activity. Design and functional testing of MG systems based on 
the L RNA-derived cis-acting elements will provide very valuable insights regarding the 
replication machinery of these arenaviruses. Based on available experimental results and our 
data, we hypothesize that mismatch between the either LASV NP and MOPV L, or LASV NP and 
the cis-acting elements from the MOPV/ML29 L-segment are responsible for the generation of 
small RNA species in cells infected with ML29 at low MOI. Notably, this mismatch does not 
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affect replication efficiency of ML29 since replication kinetics in vitro was very similar for ML29 
and parental viruses, LASV and MOPV. It is also possible that single nucleotide polymorphisms in 
ML29, particularly mutations in L protein, Y851N, R1233G, and D2136N [17], account for 
different binding ML29 NP affinity with either ML29 L or the cis-acting elements of ML29.  
Our search for “classical” defective genomes with RNA deletions in ML29-persistently-
infected cells resulted in the detection of a unique RNA band with a size slightly greater than 3 
kb in addition to the viral L RNA species. This band was observed only in persistently infected 
cells using a NB probe derived from the L RNA. This band was predominant, at least in 
VeroML29P53 cells, and can be also detected in VeroML29P28 cells (after longer exposure of NB 
to the film, Fig 10a). In general, defective viral genomes are naturally generated MG systems 
preserving terminal sequences required for replication/packaging with substantial deletions of 
internal parts of the genome. These natural MG can be used as potential broad-spectrum 
antivirals for rapidly evolved (highly heterogeneous) RNA viruses (e.g., influenza) [293]. Indeed, 
defective interfering RNAs inhibited influenza virus replication in human respiratory tract cells 
[294]. This approach can be also attractive for arenaviruses. LCMV and LASV are the most 
genetically diverse mammalian arenaviruses. Genetic diversity is one of the problems for 
development of universal LASV vaccine. To test potential antiviral activity of arenavirus MGs, we 
used recombinant LCMV L RNA-derived plasmids with deleted L protein. These plasmids, 
LCMV#1074 and LCMV#1076, contained native 3’ and 5’UTR sequences, IG region and expressed 
GFP instead of large, L protein. However, transfection of Vero cells with these plasmids did not 
affect replication of LCMV (Figure 11b). Further experiments are needed to assess role of 
defective MGs in arenavirus replication. Nevertheless, experiments with LCMV#1074 and 
LCMV#1076 MGs provide evidence that the cis-acting elements from the L-segment can be 
successfully used to design new arenavirus MG systems.  
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While we currently do not how or if the L RNA-derived small RNA species, (either from 
acute infection of persistently-infected cells), contribute to advanced attenuation and 
immunogenicity of ML29, we provided evidence that indeed ML29P50 was deeply attenuated in 
CBA/J and STAT-1-/- mice. In the future, it may be interesting to see if a blended vaccine 
formulated with interfering particles produced by persistently-infected cells will induce broad 
cross-protection against LASV strains from different phylogenetic lineages of LASV. In the STAT-
1-/- mouse model, ML29 was more attenuated than MOPV. ML29 enriched with interfering 
particles (ML29P50) induced potent T cell responses, and was fully attenuated in these mice.  
ML29P50 inoculated STAT-1-/- mice had weight loss and clinical manifestations in the 
week following vaccination (Figure 12e,f) but quickly recovered. By the end of the two-month 
observation, their weights were similar to mock treated mice. Supportive care was largely 
unsuccessful in increasing the survival of ML29 inoculated STAT-1-/- mice, but did rescue 25% of 
animals challenged with a lethal dose of MOPV. There were no signs of sensorineural hearing 
loss with ML29, MOPV, or ML29P50 mice two months following inoculation, confirming that this 
is not likely to be an adverse effect of ML29 vaccination. 
Arenaviruses, by definition, are rodent-borne viruses. These viruses are treated 
differently by the immune system of rodents and humans (or NHPs). Nevertheless, among 
experimental rodents, guinea pigs seems to be the most reliable and appropriate small animal 
model to study arenavirus-induced pathogenesis and protective immune responses. We used 
outbred Hartley guinea pigs in efforts to assess safety and cross-protective immunogenicity of 
ML29. Hartley guinea pigs vaccinated with ML29 and challenged with lethal LCMV-WE (which 
mimics LF in NHPs), were not protected. However, they still had had a modest (but statistically 
significant) delay in time to death following LCMV-WE challenge. In contrast, ML29 vaccinated 
rhesus macaques were fully protected from lethal LCMV-WE challenge [161]. This is likely due to 
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the unusually high susceptibility of these Hartley guinea pigs to LCMV-WE infection despite the 
clear presence of T-cell immunity by ELISpot (Figure 13b.) It is also possible that different T-cell 
epitopes are protective in the Hartley guinea pig model, and that these epitopes do not provide 
for heterologous protection against LCMV-WE. Challenge with guinea pig adapted LASV/Jos may 
be a more appropriate challenge model to evaluate ML29 protection. While LCMV-WE infection 
induced clear signs of renal disease (elevated blood glucose, blood urea nitrogen and amylase 
with reduce calcium) and viral hepatitis (elevated ALT, AST, GGT and reduced albumin), ML29 
and ML29P50 did not. This further demonstrates the excellent safety profile of these live 
attenuated vaccines. 
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Figures 
Figure 9. GFP expression from Vero (left), VeroML29P28 (center) and VeroML29P53 (right) cells 
infected with 3.4x104 FFU of r3LCMV-Arm-GFP/GFP at 24 (top) and 48 (bottom) hours post 
infection. 
Figure 10. (a) Northern blot of Vero cells infected with a 0.001 MOI of ML29 at the indicated 
hours post infection (Lanes 1-3), VeroML29P28 at 96 hours after passaging (lane 4), 
VeroML29P53 at 96 hours after passaging (lane 5), and uninfected Vero cells (lane 6) detected 
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with a probe targeting the N-terminus of the ML29/MOPV L-protein coding region extending 
into the non-repeated portion of the L-Segment 3’ untranslated region (left blot) or a probe 
targeting the N-terminus of the ML29 NP-protein coding region extending into the non-repeated 
portion of the S-Segment 3’ untranslated region. (b) Norther blot of Vero cells (uninfected, lane 
1) infected with a 0.001 MOI of LASV at the hours post infection indicated (lane 2-5) detected
with a probe targeting the Z protein coding region of the L-segment. The 0 HPI lane was 
collected immediately following infection. (c) Northern blot of Vero cells infected with a 0.001 
MOI of MOPV at the indicated hours post infection (Lanes 2-4) and uninfected Vero cells (lane 1) 
detected with the same probe used in (a). 
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Figure 11. (a) Schematic showing the constructs LCMV#1074 and LCMV#1076 which were 
inserted into an mPol-I driven expression vector. (b) BHK-21 cells were transfected with mPolI-
LCMV#1074, mPolI-LCMV#1076, or a pCAGGs expression vector for GFP. One day later, the cells 
were infected with LCMV-Arm at an MOI of either 0.1 or 0.5 and allowed to incubate for an 
additional day before the supernatants were collected and titered by focus forming assay. (c) 
Left two panels: BHK-21 cells were transfected with LCMV#1074 (top) or mPolI-LCMV#1076 
(bottom) and expression vectors for the two LCMV trans-acting replication factors: RdRP L-
protein (pCAGGs L) and nucleoprotein (pCAGGs NP). Right four panels: Vero cells transfected 
with LCMV#1074 (top) or mPolI-LCMV#1076 (bottom) and, one day post transfect, infected with 
a 0.1 MOI (center two panels) or 0.5 MOI (right two panels) of LCMV-Arm. Images captured 2 
days post transfection. 
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Figure 12. CBA/J mice were inoculated IC with 103 PFU of ML29 (green), a qRT-PCR equivalent 
dose of ML29P50 (red), or mock inoculated with PBS (blue) and followed for two weeks for (a) 
survival, (b) weight, and (c) clinical manifestations. Survival curves are significantly different (p < 
0.0001) by Mantel-Cox Log-rank test. STAT-1-/- mice were inoculated IP with 103 PFU of ML29 
(green), a qRT-PCR equivalent dose of ML29P50 (red), 103 PFU of MOPV (purple), or mock 
inoculated with PBS (blue) and followed for two months for (d) survival, (e) weight, and (f) 
clinical manifestations. Sixty-two days post inoculation, mice were tested for hearing loss by 
acoustic startle with a sound generated at (g) 20 dB, (h) 30 dB, or (i) 40 dB greater than the 
background noise of the room. Following the startle tone, the movement of the mouse was 
tracked with a digital pressure transducer, which recorded pressure signal as millivolts. The 
dashed line represents the sensitivity threshold used to distinguish response to the sound from 
non-specific signal. Values above the dashed line were able to hear the startle inducing tone. 
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Figure 13. (a) Hartley guinea pigs were vaccinated with 103 PFU of ML29 SC or mock vaccinated. 
Twenty-eight days post vaccination, mice were challenged with 103 PFU of LCMV-WE SC and 
followed for survival. Survival curves are significantly different (p = 0.0253) by Mantel-Cox Log-
rank test. (b) Hartley guinea pigs (n = 4 per time point) were inoculated with ML29. Blood was 
collected and PBMCs were tested for IFN-γ production in response to LASV/Jos peptide 
stimulation by ELISpot at 3, 7, and 14 DPI. ** p < 0.01 by one way ANOVA with Dunnett’s post-
hoc comparison to mock. (c-j) Blood chemistry values measured with a Piccolo Xpress analyzer 
including (c) glucose, (d) blood urea nitrogen, (e) calcium, (f) amylase, (g) ALT, (h) AST, (i) 
Albumin, and (j) GGT. ** p < 0.01, *** p < 0.001, **** p < 0.0001 by one way ANOVA with 
Dunnett’s post-hoc comparison to mock. 
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CHAPTER V 
ADVANCED SAFETY AND GENETIC STABILITY IN MICE OF A NOVEL DNA-LAUNCHED VENEZUELAN 
EQUINE ENCEPHALITIS VIRUS VACCINE WITH REARRANGED STRUCTURAL GENES2 
1. Introduction
Venezuelan Equine Encephalitis Virus (VEEV) is member of the genus Alphavirus in the 
family Togaviridae. There are six antigenic subtypes and seven varieties in the VEEV complex, 
most of which are endemic to Central and South America [295, 296]. Types IAB and IC are 
associated with epizootic outbreaks in equines, when the virus breaks from its sylvatic cycle 
between the mosquito vector and rodents or birds [295]. In equines, VEEV presents as a biphasic 
illness with high fever followed by neurologic disease, resulting in 50%−89% mortality [297]. 
During infection, equines have a high titer viremia, which can lead to subsequent transmission 
through the mosquito vector to other equines or humans [297]. However, person-to-person 
transmission has not been reported. In humans, VEEV causes a biphasic febrile illness followed 
by myeloencephalitis with high morbidity, including neurological complications, and a mortality 
rate of approximately 2% [298]. Significant overlap occurs between regions of VEEV endemicity 
and that of some other tropical disease, which complicates clinical diagnosis. In particular, it has 
been reported that overlap with areas of dengue virus infection may result in an 
underestimation of VEEV prevalence [295]. In a population-based study, the seroprevalence of 
2 This chapter is adapted from work published in Vaccines, 2020, Volume 8, Issue 1 with the 
same title under a Creative Commons Attribution (CC BY) license [27]. 
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VEEV has been reported to be as high as 75% in some endemic regions [299]. Climate change 
may be contributing to the increased geographical distribution of Culex mosquitos, increasing 
the population of humans and equine at risk for contracting VEEV [300-302]. 
VEEV was weaponized in the US and former USSR before biological warfare programs were 
discontinued [298, 303-305]. Still, VEEV is recognized as a potential biological weapon threat. In 
the US, VEEV subtypes IAB and IC are regulated under the HHS/USDA Select Agent program due 
to the severe threat posed to human and animal health, especially in the absence of FDA-
licensed human vaccines and therapeutics [306]. Due to the minimum infectious aerosol dose 
required for infection, VEEV also has a long history of being implicated in laboratory-acquired 
infections [307-309]. 
The first effort to create a VEEV vaccine used a formalin inactivated wild-type virus. 
However, these experimental vaccines had low immunogenicity and were prone to incomplete 
inactivation [310]. A live attenuated vaccine, TC-83, was developed by serially passaging VEEV 
TrD through guinea pig heart cells 83 times while monitoring virulence by intracranial (IC) 
injection in mice [13]. VEEV TC-83 contains 10 point mutations compared to the VEEV TrD strain, 
however the attenuation is attributed to two key differences: G to A mutation at position 3 of 
the 5′ untranslated region, which reduces translation efficiency by restoring Ifit1 restriction, and 
a threonine to arginine substitution at position 120 of the E2 glycoprotein [311-313]. 
Murine infection with the Trinidad-Donkey strain (TrD) of VEEV has been identified as a 
good challenge model for vaccine development, in line with the FDA animal rule [314], in 
addition to the aerosolized model of infection in Rhesus macaques. TC-83 has been tested in 
human phase I and II trials and became available for individuals “at risk” through the Special 
Immunization Program under the supervision of the United States Army Medical Research 
Institute of Infectious Disease (USAMRIID, Fort Detrick, MD) [29]. TC-83 human trials have 
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revealed high reactogenicity, often leading to symptomatic VEEV infection including febrile 
illness and headaches in up to 40% of vaccinated individuals [37, 315]. Additionally, it has been 
documented that a single dose of TC-83 is often insufficient to illicit protective humoral 
responses (neutralizing antibodies), as detected by plaque-reduction neutralization tests (PRNT). 
Individuals with poor responses are usually further immunized (boosted) with formalin-
inactivated TC-83 (called C-84) to enhance PRNT titers following TC-83 vaccination [29]. 
Experimental V3526, a rationally designed VEEV vaccine containing a mutation in the E2 
cleavage site of the structural polyprotein, showed promising results in mice. However, the 
phase I clinical trial revealed unacceptable adverse effects and development of V3526 was 
discontinued [316]. Recently, chimeric alphaviruses, either with Sindbis virus, or the insect host-
restricted Eilat virus, have been tested as VEEV vaccine platforms [37, 41, 317, 318]. An 
alternate approach has been proposed to create a novel vaccine by the introduction of an 
internal ribosome entry site to drive control of VEEV structural proteins or capsid [319-321]. 
The limited number of attenuating mutations in TC-83 and the high error rate of the viral 
RNA-dependent RNA-polymerase (RdRP) seem to be related to the instability of TC-83 
attenuation [317]. Substantial progress in alphavirus molecular virology and VEEV pathogenesis 
has provided a variety of powerful tools to address the safety and immunogenicity of the VEEV 
TC-83 vaccine. Recently, we have used several approaches to further improve the VEEV TC-83 
vaccine: (i) infectious DNA (iDNA) technology to launch a live-attenuated vaccine in vivo [322]; 
(ii) rearrangement of alphavirus structural genes; and (iii) genetic stabilization of the TC-83-
attenuated phenotype [44]. The novel V4020 experimental vaccine was rationally designed by 
securing the key TC-83 attenuating mutation (E2-T120A), along with a further improvement of 
attenuation by rearrangement of TC-83 structural genes [44]. 
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In proof-of-concept studies, V4020 provided complete protection against wild-type VEEV 
TrD challenge, inducing sterilizing immunity in mice [44]. After a single dose of either 
subcutaneous live V4020 or electroporation with V4020 iDNA, one month later, BALB/c mice 
were protected from lethal challenge with VEEV-TrD [44]. Cynomolgus macaques, vaccinated 
with either a single dose or two doses of V4020, were aviremic following an aerosol challenge 
with VEEV TrD [323]. Here, we compared the safety and genetic stability of V4020 and TC-83 in 
viral replication kinetics studies in brain tissues, and then assessed the potential to revert to a 
pathogenic phenotype during passages of the vaccines in mice. In addition to virology methods, 
NanoString gene expression profiling and RNA-Seq analysis were applied to track viral genetics 
and host responses during the replication of both attenuated viruses in brain tissues of 
experimentally infected mice. 
2. Materials and Methods
2.1. Viruses 
VEEV TC-83 was obtained from U.S. Army Medical Research and Materiel Command (Fort 
Detrick, MD, USA), and amplified once in Vero cells. The pMG4020 plasmid for launching was 
previously described [44]. VEEV V4020 virus was prepared by electroporation of pMG4020 into 
Vero cells and the generated virus particles were concentrated by ultracentrifugation [44]. Virus 
titers were determined by infecting monolayers of Vero cells in 24-well tissue culture plates with 
serial dilutions of virus stocks for 1 hour, followed by methylcellulose overlay. Three days post 
infection, cells were fixed with paraformaldehyde and stained with crystal violet to count 
infectious plaques. 
2.2. Vaccine Replication Kinetics in Brain Tissues 
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BALB/c mice (6−8 weeks old, female, 24 mice per group) were inoculated IC with 105 plaque 
forming units (PFU) of either V4020 or TC-83 in a total volume of 20 µL of PBS. To prepare for IC 
inoculation, mice were shaved, anesthetized with isoflurane in an induction chamber, 
transferred to a nose cone, had the injection site cleaned with first povidone iodine followed by 
ethanol, and positioned with their head tilted forward. A 27-guage needle (BD) was inserted 
through the foramen magnum angled to prevent damage to the brain stem. Following injection, 
mice were monitored during recovery. Mice that did not recover from the IC procedure or that 
met euthanasia criteria at 1 DPI (about 7% of all IC treated animals with no apparent association 
to treatment group) were excluded from analysis. 
Mice were weighted daily and assessed for signs of clinical disease on a 16-point scale as 
previously described [44]. Briefly, observation was based on grooming, adjusted grimace scale 
score, activity, and neurological responses including tail strength, hind leg strength, abdominal 
curl reflexes, and righting reflexes. On days 1, 2, 3, 5, 7, 9, 11 and 13-post infection, three mice 
from each group were sacrificed, and brain tissue was collected. Half of the brain was fixed in 
neutral buffered formalin for 24 hours before standard processing and paraffin embedding for 
histology. A quarter of the brain was placed in 2 ml screw top tubes with 1 mL TRIzol Reagent 
(ThermoFisher #15596026), and homogenized with glass beads in a bead beater for isolation of 
RNA by phenol-chloroform extraction. The remaining brain tissue was homogenized in cell 
culture media and clarified as described previously [204] for plaque assay. 
2.3. Sequential IC Passages in Mice 
BALB/c mice (6−8 weeks old, female, 10 mice per group) were inoculated IC, and, two days 
post infection, two mice from each group were sacrificed, brain tissue was collected, 
homogenized, clarified, aliquoted, and stored at –80 °C, as described above. One aliquot from 
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each mouse was titered by plaque assay. A second aliquot was used to prepare the inoculum for 
subsequent passages after a single freeze–thaw cycle. Each mouse was inoculated with 105 PFU 
of virus comprised of 5 × 104 PFU per dose originating from each of two mice from the previous 
passage. The remaining mice in each group were weighed daily and monitored for clinical signs 
for 14 days or until they met the euthanasia criteria of 25% weight loss or the loss of ability to 
obtain food and water for a period of 24 hours or greater (e.g., complete loss of righting reflex 
or hind leg paralysis.) At the time of sacrifice, brain tissue was collected as described above. 
2.4. In Situ Hybridization and Histology 
Formalin-fixed paraffin embedded (FFPE) brain tissue was sectioned on a Leica RM2125 RTS 
microtome to a thickness of approximately 5 μm and mounted on charged glass slides. Slides 
were baked to dry. Manual hematoxylin and eosin staining was performed as previously 
described [324]. In situ hybridization was done using RNAScope HD Assay Brown (#322300) 
using a probe targeting VEEV nsP3 (#404501, Advanced Cell Diagnostics, Hayward, CA, USA) 
according to the manufacturer’s directions. 
2.5. NanoString Array 
RNA collected during necropsy from the kinetic study on days 5, 7, 9, 11, and 13 post 
inoculation was isolated from mouse brain homogenized in TRIzol as described above. RNA was 
similarly collected from mock (PBS) IC-inoculated mice. Purified RNA was quantified on a 
NanoDrop 2000 spectrophotometer (ThermoFisher, Wilmington, DE, USA), diluted to 10 ng/µL, 
and sent to NanoString Technologies (NanoString Technologies, Seattle, WA, USA) for analysis. A 
total of 100 ng of each sample was hybridized to the nCounter Mouse Neuro-inflammation 
panel (XT-CSO-MNROI1-12) for 16 hours at 65°C. Hybridized RNA was quantified on a 
NanoString Prep Station and Digital Analyzer Max System (NanoString Technologies, Seattle, 
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WA, USA) with the manufacturer’s high sensitivity protocol. Additional probes to detect VEEV 
genes (Table 2) were designed and synthesized by NanoString Technologies (NanoString 
Technologies, Seattle, WA, USA) based on the TC-83 GenBank reference sequence L01443.1. 
These probes were additionally included in the neuro-inflammation panel.  
2.6. RNA-Seq 
Brain tissue from mice inoculated with passages one through five (P1-P5) of V4020 and TC-
83 were collected two days post inoculation, DNAse I treated (Zymo Research #E1010), and 
Table 2. NanoString probes used for the detection of Venezuelan Equine Encephalitis Virus (VEEV) 
genes. 
Target Probe 
6K 
ACAAT AACCA ACAGA TGTTC TGGAT TCAAT TGCTG ATCCC TCTGG CCGCC TTGAT 
CGTAG TGACT CGCCT GCTCA GGTGC GTGTG CTGTG TCGTG CCTTT 
capsid 
ATCGA CAACG ACGTT CTGGC CGCGC TTAAG ACGAA GAAAG CATCC AAATA CGATC 
TTGAG TATGC AGATG TGCCA CAGAA CATGC GGGCC GATAC ATTCA 
E1 
CACCA GGGTG TCAGA AACAC CGACA CTTTC AGCGG CCGAA TGCAC TCTTA ACGAG 
TGCGT GTATT CTTCC GACTT TGGTG GGATC GCCAC GGTCA AGTAC 
E2 CTTAA AAGGA AAACT GCATG TCCCA TTCTT GCTGG CAGAC GGCAA ATGCA CCGTG 
CCTCT AGCAC CAGAA CCTAT GATAA CCTTC GGTTT CAGAT CAGTG 
E3 
CCACC ATGTG TCTGC TCGCC AATGT GACGT TCCCA TGTGC TCAAC CACCA ATTTG 
CTACG ACAGA AAACC AGCAG AGACT TTGGC CATGC TCAGC GTTAA 
nsP3 GTGTG CTCAT CCTTT CCATT GCCGA AGTAT AGAAT CACTG GTGTG CAGAA GATCC 
AATGC TCCCA GCCTA TATTG TTCTC ACCGA AAGTG CCTGC GTATA 
nsP4 
GCTGG TTAGG AGATT AAATG CGGTC CTGCT TCCGA ACATT CATAC ACTGT TTGAT 
ATGTC GGCTG AAGAC TTTGA CGCTA TTATA GCCGA GCACT TCCAG 
purified with an RNeasy mini kit (Qiagen #74104.) Purified RNA was quantified on a NanoDrop 
2000 spectrophotometer (ThermoFisher, Wilmington, DE, USA) Samples were prepared for 
sequencing by rRNA depletion using the NEBNext rRNA Depletion Kit (#E6310) followed by 
library prep using NEBNEXT Ultra II RNA Library Prep with Sample Purification Beads (#E7775, 
NEB, Ipswich, MA, USA.) Libraries were quality checked on an Agilent BioAnalyzer before 
sequencing on an Illumina NextSeq 500 with a NextSeq 500/550 High Output Kit v2.5 (75 Cycles) 
kit (#20024906, Illumina, San Diego, CA, USA.) 
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The sequencing files were imported into Galaxy [325], trimmed using trimmomatic version 
0.36.6 [326], aligned to viral reference sequences with BowTie 2 version 2.3.4.2 [327], and a 
pile-up was generated, filtered and exported to Excel for statistical analysis. Sequences not 
aligning with the viral references were aligned with the mouse mm10 genome (GenBank 
assembly accession GCA_000001635.8) using HiSat2 version 2.1.0+galaxy4 [328]. Mouse 
transcripts were quantified with htseq-count version 0.9.1 [329] and screened for differential 
gene expression by DESeq2 version 2.11.40.2 [330]. Gene ontologies relating to differential gene 
expression were detected by goseq mapping software version 1.26.0 [331]. 
2.7. Statistical Analysis 
Results showing weights, clinical scores, or viral plaque assay titers are presented as mean ± 
SEM using the GraphPad Prism version 7 for Windows package (GraphPad Software, LaJolla, CA, 
USA). Prism was also used for statistical significance testing, as indicated in the applicable figure 
legends, and to visualize data from NanoString and RNA-Seq experiments as heat-maps. 
NanoString nSolver software (NanoString Technologies, Seattle, WA, USA) was used to 
generate all presented volcano plots and the data presented in supplemental Table 1 and 3. 
nSolver also calculated relative cell marker expression. Differences in cell marker expression 
were tested for significance in Prism by two-way ANOVA followed by Fisher’s LSD post-hoc 
analysis. 
NanoString nSolver Advanced Analysis 2.0 software was used to calculate pathway scores. 
Pathway scores are calculated based on the first principal component of each measured gene in 
the KEGG pathway. These differences are then quantified based on the normalized expression of 
all genes belonging to the pathway. This summarizes the involvement of each tested KEGG 
pathway for each biological replicate relative to all samples included in the analysis. Pathway 
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scores summarize whether the overall gene expression in a pathway is up- or down-regulated. 
Values for pathway score were exported from nSolver, normalized to mock infected controls, 
and tested for significance in GraphPad Prism using a two-way ANOVA with Dunnett’s post-hoc 
comparison to the mock IC treated group. 
NanoString nSolver Advanced Analysis 2.0 software also calculates a “Global Significance 
Score” (GSS) for a group of samples by measuring the overall differential expression of all genes 
belonging to a particular KEGG pathway, while ignoring whether each gene is up- or down-
regulated. GSS is different from pathway score because it summarizes how much difference 
there is in pathway involvement between groups. GSS allows for the easier comparison of many 
pathways between groups, but does not provide meaningful data about the magnitude of 
overall gene expression. 
2.8. Ethics Statement 
All animal experiments were conducted under protocols approved by the University of 
Louisville institutional animal care and use committee. Work with live VEEV was conducted at 
the National Institutes of Health Regional Biocontainment Laboratory on the University of 
Louisville campus and was done with University of Louisville institutional biosafety committee 
approval. TC-83 and V4020 were handled with BSL2/ABSL2 practices and are exempt from US 
federal select agent regulations. Passaging of V4020 and TC-83 in mouse brains was done at 
ABSL3. 
3. Results
3.1. Kinetics Study: Attenuated Replication of V4020 in Brains of Infected Mice 
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To assess replication kinetics in brain tissues, two groups of BALB/c mice were inoculated 
with 1 × 105 PFU of either V4020 or TC-83 via the IC route. At 1−2 day intervals, three mice from 
each group were euthanized and brain samples were taken to determine infectious viral load by 
plaque titration. Mice from both experimental groups showed symptoms of disease and lost 
weight (Figure 14b), while a control group of mock-infected mice did not show clinical scores 
during the observation period (Figure 19). We previously documented that higher clinical scores 
correlated with weight loss in this model [44]. Direct comparison of percent weight loss to viral 
load reveals key differences between V4020 and TC-83 at 7 DPI (Figure 14b). Replication kinetics 
of both attenuated viruses showed similar patters during the first 3 DPI, reaching peak titers of 
109 PFU per gram of brain tissue at 2 DPI. After 3 DPI, V4020 replication rapidly declined, with a 
significant decrease in viral titer at 5 DPI. No infectious V4020 viruses were detected at 7 DPI or 
at later time points. Conversely, infectious TC-83 was detected at 7 DPI and 9 DPI (with titers of 
105 and 104 PFU/g respectively). The high viral loads in TC-83-infected mice seemed to drive 
more aggressive weight loss than was observed in V4020-inoculated mice (Figure 14b).  
In line with infectious viral load results, RNAScope in situ hybridization detected strong and 
extensive signals in the brain tissues of both groups of mice at early stage of the infection 
(Figure 15, 2 DPI, brown staining). In V4020-infected mice, these signals declined at 5 DPI and 
were not detectable at later time points. In contrast, in TC-83-infected mice, strong positive 
hybridization signals remained in brain tissues of TC-83 mice until 9 DPI and were still detectable 
as late as 13 DPI (Figure 15). Histology (H&E staining) did not reveal clear differences between 
two groups of mice. Nevertheless, in TC-83-infected mice at 5 DPI, there was a notable increase 
in perivascular cuffing, a key indicator of VEEV brain inflammation (Figure 15, H&E panels, 
arrowed). In summary, the replication kinetics study documented a more attenuated profile of 
VEEV V4020 replication in comparison with the VEEV TC-83 experimental vaccine. 
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3.2. Neuro-Inflammation in Brain Tissues of Mice Infected with V4020 vs. TC-83 Assessed by 
Direct Multiplexed Measurement of Gene Expression 
NanoString nCounter gene expression technology allows direct measurement of mRNA 
expression levels in tissues without enzymatic reactions [332]. This technology is more sensitive 
than DNA microarrays and comparable to real-time PCR measurements for individual genes 
[333, 334]. In this study, the commercially available Mouse Neuro-Inflammation color-coded 
probe panel [335], enabling the quantification of 770 genes involved in 23 KEGG-pathways and 
processes, was used to assess host cell responses in brain tissues of V4020- and TC-83-infected 
mice. In addition, customized barcoded VEEV-derived probes were designed and included in this 
panel to detect and quantify the expression of individual VEEV genes. 
Pathway scoring is a summary statistic that reflects the relative KEGG pathway involvement 
based on gene expression. As seen in Figure 16, inflammatory and cytokine signaling, as well as 
innate and adaptive immune response pathways, were significantly upregulated in both TC-83 
and V4020-inoculated mice compared to mock-inoculated controls at 5 and 7 DPI. However, the 
magnitude of upregulation is much greater for TC-83 compared to V4020, and remains 
significantly higher than mock-infected mice at 9 and 13 DPI. Conversely, in V4020-inoclulated 
mice, pathways scores declined and are no longer statistically different from mock treated 
animals by 9 DPI (Figure 16a). In general, pathway scores peak at 5 DPI for VEEV V4020 and 9 
DPI for VEEV TC-83 (Figure 16a) which corresponds to the last day that infectious viral particles 
are detected by plaque assay in brain tissue (Figure 14b). 
Volcano plots provide visualization of the magnitude of differential gene (host and viral) 
expression in V4020 treated mice compared to TC-83 (X axis, log2[fold change]), along with 
statistical significance (Y axis, -log10[P-value]). There were no significant differences in gene 
expression patterns at 5DPI (Figure 20a). At 7, 9 and 13 DPI, VEEV viral genes were 
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downregulated in V4020-inoculated mice compared to TC-83-inoculated animals (Figure 16b–d, 
named viral genes, red [p < 0.01] and green [p < 0.001] colored genes). At 9 DPI, the greatest 
number of genes displayed large log2-fold changes, and the changes were highly statistically 
significant (Figure 16c). Among these, host genes related to inflammation (labeled by orange 
boxes) were clearly identified. These inflammation related genes were less abundant at 13 DPI 
(Figure 16d). All differentially expressed genes, with a greater than 2 log2-fold change in at least 
one passage, are listed in Table S1. VEEV viral genes E1, 6K, nsP4, nsP3, E2, capsid protein and 
E3 showed the greatest average magnitude of change, followed by host genes related to 
inflammation, including interleukin 1 receptor antagonist (Il1rn), granzyme B (Gzmb), 
macrophage scavenger receptor 1 (Msr1), leukocyte immunoglobulin like receptor B4 (Lilrb4a), 
granzyme A (Gzma) and chemokine genes (Ccl2, Cxcl10, ccl7, Cxcl9). 
A heat-map of GSS scores showed clearly distinguished patterns between V4020 and TC-83 
samples (Figure 20b). The GSS scores for mock and V4020 inoculated mice at 9DPI were very 
similar across all pathways, suggesting the processes involved in neuro-inflammation, damage, 
repair and adaptive immune responses have returned to baseline values at this time point. 
Meanwhile, “inflammatory signaling” and “neuron and neurotransmission” GSS had markedly 
different patterns between V4020 and TC-83 groups (Figure 20,c,d, respectively). 
NanoString technology can also quantitate predicted cell type abundance based on mRNA 
expression probes specific for cell type markers presented in the Mouse Neuro-inflammation 
panel. Markers of macrophages, DCs, and microglia were expressed with statistically significant 
differences in brain tissues of V4020 mice in comparison with TC-83-inoculated mice. As seen in 
Figure 16e, in brain tissues of TC-83-inoculated mice, the expression of DC markers was strongly 
upregulated at 5, 7, and 9 DPI. Macrophage cell markers were generally upregulated in TC-83 
compared to V4020, with statistically significant differences at 5 and 13 DPI. In addition to 
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macrophages, markers of microglia were also clearly upregulated in TC-83-inoculated mice. In 
summary, direct multiplexed measurement of genes involved in mouse neuro-inflammation 
pathways clearly demonstrated upregulated patterns of genes involved in neuro-inflammation 
in mice inoculated with VEEV TC-83 versus VEEV V4020. 
3.3. Clinical Profiling of Mice during Serial Intracranial Passages of V4020 and TC-83 
Serial IC passages in mice are widely used to assess the phenotypic and genetic stability of 
alphavirus attenuation. This approach was used to compare the V4020 and TC-83 experimental 
vaccines. As seen in Figure 17, five sequential IC passages (P1-P5) of V4020 and TC-83 in BALB/c 
mice resulted in striking differences in clinical profiles. First, throughout the five serial passages, 
all V4020 treated mice survived, while three out of eight TC-83 mice met euthanasia criteria in 
the groups which received passage 2 (P2) and P3 virus (Figure 17a-b). Second, measurement of 
viral load at 2 DPI in brain tissues of mice revealed lower titers during P1-P3 in V4020 mice, and 
these differences were statistically significant. (Figure 17c). Third, mice infected with V4020 
isolated from previous brain passages tended to have weight loss predominantly during the first 
3 DPI, then gained weight after this time point. Some mice (e.g., in P1- and P2-V4020 groups) 
nearly fully recovered their initial weight by the end of observation period (Figure 17d). In 
contrast, mice in TC-83 groups tended to have a prolonged, more profound, weight loss. No 
mice in TC-83 groups recovered their initial weight (Figure 17e). Finally, clinical scoring of mice 
revealed that mouse-brain-passaged V4020 had clinical manifestations peaking at 2-3 DPI. After 
this time point, clinical signs were ameliorated in all mice, and, after 7-8 DPI, no V4020 animals 
had scored clinical symptoms (Figure 17f). In great contrast, mouse brain passaged TC-83 caused 
more severe clinical scores that persisted in some mice at 14 DPI (Figure 17g). Interestingly, 
clinical symptoms of TC-83 inoculated animals displayed a biphasic pattern (e.g., P3 and P4 TC-
93 
83, Figure 17g). These results indicate that IC passages of the VEEV V4020 experimental vaccine 
did not result in a change in the pathogenic profile from the initial V4020 inoculation (P1). In 
contrast, VEEV TC-83 passages resulted in the generation of viruses which caused aggravated 
experimental disease, which resulted in the euthanasia of 13.3% of TC-83 treated mice. 
3.4. Viral and Host RNA-Seq Profiles of Brain Samples, P1-P5 
During serial passaging in brain, RNA samples from tissue samples collected at 2 DPI were 
analyzed by Illumina NextSeq 500 to assess genetic variations in V4020 and TC-83 viral 
populations. In general, as seen in Figure 18a, the V4020 virus had lower rates of mutations that 
had high statistical significance throughout passages P1-P5 (downward spikes in blue for V4020 
or grey for TC-83). Read depth among sequenced samples depicted in red for V4020 or purple 
for TC-83 was similar (Figure 18a). At 2 DPI, neither virus showed signs of selective pressure 
driving the reversion of either of the key attenuating mutations: the 5′UTR position 3-A or the 
E2-120 codon (Figure 18b). The rates of transversion and transition mutations were similar 
among all samples (Figure 21a,b). Synonymous to non-synonymous mutation ratios (SMR) were 
significantly lower for nsP1 and nsP2 genes and elevated for nsP3 genes in samples derived from 
both viruses (Figure 18c). The SMR ratio tended to increase for highly statistically significant 
mutations (Figure 21c). Interestingly, a significantly higher SMR was observed in the nsP4 (RdRP) 
gene of TC-83 compared to V4020. In particular, many more nucleotide variants (NVs) were 
detected in nsP3 and nsP4 of passage 2 and 3 of TC-83 than V4020, with several of these 
persisting through passages 4 and 5. Fewer NVs were observed in the capsid gene of V4020, 
with the largest differences in P2, P3, and P4. 
Sequence reads mapping to the murine host allowed a basic analysis of the host response 
at 2DPI for V4020 compared to TC-83 infected mice. DESeq2 analysis with two factors, virus 
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(V4020 or TC-83) and passage number, revealed 21 differentially expressed host genes. 
However, none of these appear to segregate in a clear way to inoculation with V4020 or TC-83 
(Figure 22a). A full list of differentially expressed host genes generated by DESeq2 in both the 
two factor analysis and, for (one factor, virus,) of each passage is presented in Table S2. Based 
on RNA-Seq at 2 DPI and NanoString analysis from 5-13 DPI, 97 host genes were identified to be 
differentially expressed between V4020, and TC-83 in both assays (Table S3). Interestingly, 
among these genes—immune regulators Tbx21 (a key regulator of cytotoxic T-cell response) and 
Eomes, complement genes C1qa and C1qb, the cytokine Cx3cl1, and the lysosomal marker 
Lamp2—were identified as being differentially expressed in relation to both virus and time point 
(Table S3, fold changes in V4020 compared to TC-83). Ontological analysis of differentially 
expressed genes compiled from each individual passage highlighted that the pathways most 
likely to be differently regulated in V4020 compared to TC-83 IC-inoculated mice at 2 DPI 
predominantly involve neurogenesis and brain function (Figure 22b). In summary, RNA-Seq 
profiling of samples collected at 2 DPI during serial passages revealed lower rates of viral 
mutations in V4020 samples, and different patterns of host gene expression associated with 
neurogenesis and brain function in V4020- and TC-83-inoculated mice. 
4. Discussion
Historically, live attenuated vaccines against viral infections have been among the safest 
and most efficacious medical interventions, and they continue to be the most cost-effective 
preventive measures [1, 336]. In recent years, live attenuated vaccines against influenza 
(FluMist), rotavirus (Rotarix) and herpes (Zostavax) infections were licensed for human use. This 
indicates that the powerful tools of molecular virology which are currently available can be 
successfully applied to address the inherent weaknesses of these vaccines: genetic stability and 
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reversion to wild-type phenotypes [337]. The TC-83 vaccine for VEEV was developed almost 60 
years ago using the “classical” technique of multiple passages in vitro and in vivo, which resulted 
in two attenuating mutations, the first in the 5′-end untranslated region, position 3 (G > A) and 
the second in the E2 envelope glycoprotein, position 120 (Thr > Arg) [13]. Since the 1960s, 
despite numerous attempts to develop better vaccines, TC-83 is the only vaccine in human use 
under an IND protocol (Special Immunization Program) which has allowed it to be tested in 
Phase II trial (NCT03531242, NCT00582504, NCT00582088, NCT03051386, 
https://ClinicalTrials.gov). Nevertheless, TC-83 is reactogenic and poorly immunogenic in ~ 18%-
20% of vaccinees, which raises serious safety concerns. 
The small number of attenuating mutations seems be associated with the genetic instability 
and reactogenicity of TC-83. To address this issue, we have applied several approaches to 
develop an advanced VEEV vaccine, V4020 [44], including: (i) rearrangement of structural genes, 
(ii) introduction of an additional sub-genomic promoter (26S) downstream from the 
glycoprotein genes; (iii) synonymous translational codon replacement to secure the attenuating 
E2 mutation TC-83; and (iv) the rescue of V4020 from a molecular clone (cDNA) to limit the 
population heterogeneity of the V4020. Here, we compared the replication kinetics of V4020 
and TC-83 in the brain following IC inoculation of mice, and performed five IC mouse passages, 
using brain tissues as the source of the virus, to assess the genetic stability and heterogeneity of 
these experimental vaccines. 
It is cannot be excluded that incomplete attenuation, characterized by the emergence of 
viruses with reversions, is responsible for the pathogenic features and adverse effects of TC-83 
vaccination [303]. Notably, viruses with reversion mutations have been isolated from throat 
swabs of individuals vaccinated with TC-83 (Jahrling PB, unpublished data) [36]. Antiviral host 
responses following inoculation, along with the delay in the virus reaching the CNS, probably 
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have synergistic effects on the attenuation of neuro-virulence. IC inoculation of experimental 
mice is a useful tool for short-cutting the natural infection route and directly examining the 
neuro-virulence of live attenuated vaccines. 
We have shown here that IC inoculation of VEEV V4020 resulted in a more attenuated 
pattern of replication compared with TC-83, as determined by clinical manifestations (weight 
loss) and viral load in brain tissues of BALB/c mice (Figure 14b). The most striking difference 
between two infections was more than 2 log10 differences in infectious viral load (PFU/g) in the 
brain at 5-7 days after IC inoculation. This was in line with RNAScope in situ hybridization data 
(Figure 15). High viral load seemed to be the major driving force, resulting in a spike in weight 
loss (which has previously been shown to correlate with clinical score [44]) at this time point in 
TC-83-infected mice. 
C3H/HeN mice are considered a more susceptible VEE model in comparison to BALB/c mice 
[338]. However, IC inoculation of BALB/c with wild-type VEEV TrD and C3H/HeN mice with wild-
type VEEV TrD or with VEEV TC-83 resulted in the same LD50 value, around 20 PFU [36]. In 
contrast, the experimental VEEV V3526 vaccine was not lethal in C3H/HeN mice. However, the 
poor safety profile of this vaccine in Phase I trial prevented further development [32]. The 
predominant adverse effects of VEEV TC-83 tend to be fever and headache [315], which coincide 
with the key symptoms of natural human VEEV infection [339]. In non-human primate models, 
central nervous system (CNS) invasion by TC-83 causes perivascular infiltration, gliosis, and signs 
of neurological disease [35]. IC inoculation of BALB/c mice recapitulates key features of neuro-
virulence following TC-83 vaccination including perivascular cuffing (Figure 15), monocyte 
accumulation in the CNS (Figure 16e,) and clinical signs of infection (Figure 14b, and Figure 17). 
NanoString technology with a custom-made panel of barcoded probes for individual viral 
genes, combined with a commercially available mouse neuro-inflammation panel, allowed the 
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direct detection and assessment of the involvement of viral and host genes in neuro-
inflammation of brain tissues in V4020- and TC-83-inoculated BALB/c mice. Volcano plots clearly 
illustrated differential expression of the genes in V4020 mice versus TC-83 mice at 5, 7 and 9 
DPI, and (among host genes) genes related to inflammation pathways and processes prevailed in 
TC-83 mice (Figure 16, Table S1). In line with these results, markers of macrophages, DCs, and 
microglia were strongly upregulated in TC-83-infected mice, suggesting the involvement of these 
cells in inflammation. As further evidence that immune infiltration into the brain is responsible 
for weight loss and clinical manifestations (Figure 14), histology revealed perivascular 
inflammation foci in TC-83 brain H&E-stained sections (Figure 15, H&E staining, arrowed). 
Reversion to a neuro-virulent phenotype represents the greatest risk in using a live 
attenuated vaccine against VEEV [317]. It has been reported that attenuated strains of VEEV can 
revert to causing neuro-virulence in as few as three serial passages in mouse brain [13, 340]. 
Indeed, in our experiments P3 and P4 TC-83 isolates induced clinically manifested infection and 
death. Interestingly enough, after serial passages in brain, TC-83 induced a biphasic disease 
(Figure 17g), a classical description of the murine model of wild-type VEEV [303]. In contrast, 
after five IC passages, V4020 did not induce lethal disease. Clinical manifestations were mild or 
moderate and disappeared in most animals within one week of IC inoculation. VEEV 
pathogenesis seems to be due to complex polygenic traits that are difficult to relate to NVs in 
the viral genome [304]. Unique NVs were not detected from more neuro-virulent passages of 
TC-83. However, TC-83 viruses from passages P2 and P3 had a high level of NVs which mapped 
within nsP4 versus V4020 viruses (Figure 18a). SMR, defined as the total number of base pair 
mutations without change in the amino acid code divided by the total number of base pair 
mutations, was used to detect purifying selection as the evolutionary mechanism of VEEV 
evolution [341]. For both TC-83 and V4020 experimental vaccines, which nearly completely 
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share a sequence identity (except, as previously noted, for V4020 rearrangement and stabilizing 
E2 position 120 mutation), nsP1 and nsP2 had significantly reduced SMR over five serial 
passages in mouse brain, suggesting that mutation in these genes is likely deleterious. 
Conversely, E3 had an increased SMR. While the time was too short (2 DPI) to consider selective 
pressure and adaptive immunity involvement, it is interesting to note that E3 has been 
identified as a key target of humoral responses which are protective against VEEV-TrD [342]. It 
has been reported that TC-83 strains with lower-fidelity RdRP are more attenuated and 
immunogenic [343]. nsP4, the viral RdRP [304], had a higher SMR in TC-83 than V4020, however 
we did not detect differences in mutation frequency across the genome (Figure 21d), suggesting 
that no real difference in RdRP fidelity arose during passaging.  
5. Conclusions
The lack of apparent differences in mutation frequency at key attenuating mutations, and 
the further lack of evidence for any positive selection during the time points studied, suggests 
that the strategy of stabilizing the E2 T120A is valid to decrease the appearance of revertants 
which would potentially arise by random mutation in the viral quasi-species at the peak of viral 
replication following vaccination. Structural rearrangement seems to additionally secure the 
attenuated phenotype of V4020. Taken together, these results indicate that V4020 is a safer and 
genetically more stable alternative to TC-83. Successful testing of V4020 in a non-human 
primate aerosol challenge model provides an additional argument for the clinical development 
of this experimental vaccine [323]. 
Supplementary Materials: The following are available online at 
https://doi.org/10.3390/vaccines8010114, Table S1: Differentially expressed genes detected by 
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NanoString, Table S2: Differentially expressed genes for a “virus x passage” RNA-Seq model, 
Table S3: Differential expression of genes detected by both NanoString and RNA-Seq.  
Supplemental Table Legends: 
Supplemental Table 1. Mouse and viral genes that were differentially expressed with an 
adjusted p-value < 0.05 and an absolute value of log2(FC) > 2 from the NanoString nCounter 
neuro-inflammation array with probes for viral genes added. Fold changes (FC) are reported as 
the change in V4020 expression compared to TC-83. Adjusted p-values were computed by 
nSolver using a model to compare individual samples by day of collection. 
Supplemental Table 2. Mouse genes that were differentially expressed with an adjusted p-value 
<0.05 from RNA-Seq on 5 passages of V4020 and TC-83 in mouse brain as reported by DESeq2 
model of virus x passage or for comparison of samples in individual passages. FC are reported as 
the change in V4020 expression compared to TC-83. Adjusted p-values are based on the 
Benjamine-Hochberg correction.   
Supplemental Table 3. Concatenation of gene fold change and significance from Table S1 and 
Table S2 for genes that were present in both NanoString and RNA-Seq analysis. 
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Figure 14. (a) Schematic diagram of the genomic structure of VEEV strains TrD, TC-83, and 
V4020. Red vertical lines denote nucleotide variants (NVs) with differing sequence from the 
TrD wild type strain which are not thought to play a key role in attenuation. Green vertical 
lines denote NVs with differing sequence between TrD and TC-83 which do play a key role 
in attenuation. A blue vertical line is used to denote the stabilized E2 120Arg NV in V4020. 
(b) Replication kinetics of V4020 and TC-83 in the brain of BALB/c mice (n = 24 per group) IC 
inoculated with 1X105 PFU of either V4020 or TC-83 and monitored daily for 13 days. 
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Weight loss (VEEV TC-83 in red square symbols and VEEV V4020 in blue circle symbols.) On 
days 1, 2, 3, 5, 7, 9, 11, and 13 post inoculation, 3 mice per time point from each group 
were necropsied and brain tissue was prepared for VEEV infectious titration by plaque 
assay to assess viral load in brain tissues (VEEV TC-83 in red bars and VEEV V4020 in blue 
bars plotted against the left Y axis). 
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Figure 15. In situ hybridization by RNAScope and H&E histology of brain sections. Stained 
tissue sections of V4020 and TC-83 brain tissue on day 2, 5, 7, 9, and 13-post IC inoculation. 
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Brown staining in RNAScope images indicates the presence of viral RNA detected by an 
nsP3 in situ hybridization probe. Representative images at 50X magnification for RNAScope 
and 100X for H&E are shown. Arrows are used to indicate perivascular cuffing. 
Figure 16. Detection and profiling genes involved in neuro-inflammation pathways. RNA 
was isolated from the brains of mice inoculated with V4020 or TC-83 and was quantified by 
NanoString nCounter assay using the mouse neuro-inflammation panel with additional 
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probes to detect VEEV genes. (a) NanoString nSolver software was used to calculate a 
pathway score to summarize the differential expression data from all genes in the pathway 
based on the first principal component of normalized gene expression. Pathway scores 
were normalized to the average score for mock IC inoculation. Two-way ANOVA followed 
by multiple Student’s t-tests with Dunnett’s correction were used for post-hoc comparison 
to mock inoculated controls. * p < 0.01, # p <.001, + p < 0.0001. Volcano plot presentation 
of differential gene expression in V4020-infected mice compared to TC-83 inoculated mice 
on (b) day 7, (c) day 9, and (d) day 13. Differentially expressed genes color coded according 
to adjusted significance where genes in red above the solid line represents the threshold of 
p < 0.01 and genes in green are above the dashed line which represents p < 0.001. Genes 
relating to the inflammatory KEGG pathway are labeled and shown in orange boxes (and 
are not additionally color coded by significance, but this can be determined by the lines on 
the graph). All significantly differentially expressed genes, (or the top 50 overall most 
significant genes for 7 DPI) have text names. (e) Cell type abundance in brain samples was 
determined by markers present in the NanoString mouse neuro-inflammation panel on 
days 5, 7, 9, and 13 with significance determined for each time by a two-way ANOVA 
without matching followed by Fisher’s LSD post-hoc analysis. * p < 0.05, ** p< 0.01, **** p 
< 0.0001. 
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Figure 17. Groups of BALB/c mice (n = 10) were inoculated via the intracranial route with 
1x105 PFU of either V4020 or TC-83. Two days after inoculation, two mice from each group 
were sacrificed, their brains were collected, homogenized, and used to make clarified viral 
stocks for inoculation of a subsequent group. This process was repeated four times for a 
total of five passages including the initial inoculation (named in the schematic of PX-Virus 
where X is the passage number and virus is either V4020 or TC-83.) Survival of (a) V4020 
and (b) TC-83 passage groups was tracked during this time. (c) Brain titers from the mice 
sacrificed on day 2 post inoculation. Two-way ANOVA followed by Fisher’s LSD post-hoc 
analysis were used to compare viral titers, * p < 0.05, ** p < 0.01. Daily weights (d) (e) and 
clinical scores (f) (g) were taken from the remaining mice challenged with either V4020 (d) 
(f) or TC-83 (e) (g) daily for 14 days. 
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Figure 18. RNA-Seq by Illumina NextSeq was run on rRNA depleted RNA isolated from brain 
tissue of mice receiving passaged virus on day 2 post IC inoculation. Sequences were quality 
trimmed with trimmomatic and aligned to VEEV TC-83 or V4020 reference sequences with 
BowTie2. Pile-ups were generated and filtered in Galaxy before being exported to excel to 
calculate normalized read depth (a), statistical significance of mutations (a), mutation 
frequency (b) and SMR (c). (a) Normalized read depth plotted on the left y-axis (red for 
V4020, purple for TC-83) was calculated by dividing the number of virus-aligned reads at 
each position by the sum of the number of reads for every position. Statistical significance 
of mutation rate as a Z-score plotted by nucleotide position on the right y-axis (blue for 
V4020 and grey for TC-83) was calculated in Excel using the “NORM.DIST” function to 
calculate a probability density function based on the mean and standard deviation of each 
biological sample. The boundaries between genes and certain features are marked with a 
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dashed vertical line and labeled at the bottom of the panel. Z-scores over 10-25 are reported 
as this value. Passages 2-5 of V4020 and Passage 1 of TC-83 are the average of 2 biological 
replicates. All other data are representative of a single biological replicate. (b) Mutation 
frequency calculated as a ratio of a mutation occurring at the identified location divided by 
the total number of reads for each reported location for V4020 (blue) and TC-83 (red). (c) 
SMR for the overall coding sequences and individual genes of V4020 (blue) and TC-83 (red). 
* p < 0.05 for the indicated gene compared to the overall SMR by one-way ANOVA with
Dunnettt’s post-hoc test , # p < 0.05 for the SMR of nsP4 in V4020 compared to TC-83 by 
student’s t-test. Data in this figure are averaged from 2 mice per group except for V4020 
passage 1 and TC-83 passages 2 through 5 which represent a single mouse.  
Figure 19. A group of BALB/c mice (n = 5) were inoculated IC with 10 μl of normal saline as a 
control for animals similarly inoculated with virus. These mice were followed for 14 days for 
(a) weight, (b) clinical score, and (c) survival. 
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Figure 20. RNA was isolated from the brains of mice inoculated with V4020 or TC-83 as 
described in Figure 16  and was quantified by NanoString nCounter assay using the mouse 
neuro-inflammation panel with additional probes to detect VEEV RNA. (a) Differential gene 
expression in V4020 compared to TC-83 inoculated mice on day 5. (b) NanoString nSolver 
software was used to calculate a GSS (a measure of the overall differential expression of 
genes belonging to a particular KEGG pathway ignoring whether each gene is up- or down-
regulated) for each experimental grouping. Calculated NanoString GSS of the (c) 
inflammatory signaling and (d) neurons and neurotransmission gene sets for V4020 (blue) 
and TC-83 (red) on the indicated days.  
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Figure 21. Frequency of transitions and transversions by base pair calculated as the counts 
of the specified mutation occurring divided by the total reads at all positions with the 
specified reference nucleotide grouped by (a) virus and passage or by (b) virus. (c) The SMR 
for all positions (overall) with a significance of Z-score less than the indicated value. (d) 
Mutation frequency by virus and passage for the whole virus genome from 2 DPI RNA-Seq 
calculated as the sum of the number of non-reference reads at every position divided by 
the sum of the total number of reads at every position. 
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Figure 22. RNA-Seq data was generated and trimmed as described in Figure 18. All analysis 
described was performed using the named modules in the Galaxy web-based platform. 
Sequences were aligned to the mouse mm10 genome using HiSat2, and features were 
counted with htseq-count. (a) All genes with significant differential expression in a model 
accounting for both virus vaccine strain and passage number are presented in a heat map 
showing fold change. All genes with differential expression with an adjusted p-value greater 
than 0.05 from each individual passage that were detected by DeSEQ2 were used as the 
input to run GOseq on each passage individually. The pathways reported by GOseq for each 
passage were combined and sorted by significance. (b) The overall top 50 over-represented 
ontologies are displayed in a heat map depicting the associated adjusted p-value associated 
with the likelihood of over-representation from GOseq. p-values less than 10 -10 are 
reported as 10-10. 
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CHAPTER VI 
DISCUSSION AND CONCLUSIONS 
Discussion 
Applications of arenavirus L derived minigenome systems to study L-segment cis-acting factors 
The L-segment based MG system will allow future studies to elucidate the role of cis-
acting factors (namely the 3’ untranslated region, the intergenic region (IGR), and the 5’ 
untranslated region) in interactions with the viral RdRP L and NP. This will facilitate the 
elucidation of the mechanisms responsible for the generation of the L-segment small RNAs that 
arise during ML29 replication (Figure 10). rLCMV containing a L segment where the IGR has been 
replaced with the S segment IGR is deeply attenuated [344]. We speculate that the mismatch of 
the ML29 (MOPV derived) L IGR with LASV NP protein may play a role in the generation of small 
RNAs observed. Additionally, further inquiry is needed to determine if the rescue of tri-
segmented arenaviruses with duplicated L-segments is possible. It is thought that the limiting 
factor for inclusion of segments in virions for arenavirus rescue is the overall size of the 
combined genome [345]. If a tri-segmented L based particle can be generated, it may 
additionally be possible to generate quad-segmented particles if the additional genes have a 
total length of no more than around 3 kb.  
While tri-segmented reporter expressing viruses are typically not as fit as their wild-type 
counterparts in vitro [283], they still may be a useful tool to study the generation of DIPs. In a 
proof of concept study, mice generated immunity to reporter sequences included in tri-
segmented ML29 viruses [346]. This suggests that despite differences in fitness, tri-segmented 
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viruses could be used for in vivo imaging of reporter expressing genes to track the establishment 
of persistent infection. The L-segment MG system can also be used as the basis to study the 
generation of DIPs by providing different reporters expressed from the Z and L loci to track the 
relative expression of Z and L genes. If there were DIG competition for viral replicase complexes, 
this could be observed as a uniform decrease in the reporter signal from any of the promoter 
genes. Over expression of the Z protein from both LCMV and TCRV interferes with transcription 
and replication, a phenomenon known as Z mediated superinfection exclusion [248, 347]. To 
exclude the possibility that there is an over production of matrix protein causing Z mediated 
superinfection exclusion, the ratio of Z loci reporter to L loci reporter would be observed. 
Tri-segmented viruses may also be useful for the expression of additional antigens in 
arenavirus LAVs. For ML29, the additional gene segments could be used to include epitopes 
from diverse strains of LASV, or even other circulating viruses. LASV and EBOV co-circulate, and 
result in LF and Ebola virus disease (EVD) with similar symptoms [348]. The currently approved 
vaccine approaches for EBOV rely on LAV vectored vaccines [6], which leads us to hypothesize 
that a tri-segmented ML29 expressing EBOV antigenic determinants could be a useful vaccine 
with coverage against both African hemorrhagic fever viruses. 
Rearrangement of structural genes is a useful tool to generate attenuated alphavirus vaccines 
Genetic rearrangement of the structural genes of VEEV was demonstrated to be a useful 
tool to further attenuate alphavirus vaccine candidates. Partial transcription termination, where 
the viral RdRP will fall off of the template between genes leads to increased expression genes 
that are closer to the native 26S sub-genomic promoter [349]. As a result, the rearrangement 
and addition of a second 26S sub-genomic promoter likely changes the ratio of capsid to 
glycoprotein produced in VEEV V4020 compared to VEEV TC-83. While clear differences in the 
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viral gene expression between VEEV V4020 and VEEV TC-83 were observed (Figure 16), the 
mechanisms of attenuation that are attributable to the additional promoter remain unclear. 
However, the shift in the ratio of capsid to glycoprotein would likely decrease the efficacy of 
virion assembly. We hypothesize that this could be observed in differences in the ratio of 
particles (detected by qRT-PCR, which would also allow the detection of DIPs) to infectious units 
(detected by FFU or PFU). If this were the case, perhaps due to the contribution of DIPs, a higher 
particle to PFU ratio would be observed in VEEV V4020 compared to VEEV TC-83. Additionally, 
rearrangement of the structural genes could be a useful tool to generate other attenuated 
alphaviruses for use as LAVs, or to enhance the attenuation of other LAV candidates.  
Defining the pathogenic determinants of passaged VEEV infection 
Both VEEV TC-83 and VEEV V4020 replicated to high titer in the brain of IC challenged 
mice by 2 DPI. We made three key observations about the emergence of pathogenicity i) there 
are differences in virulence that emerge between passaged VEEV TC-83 and VEEV V4020, ii) 
neither the key attenuating mutations nor any of the other SNPs between VEEV TrD and VEEV 
TC-83 are reverted at 2 DPI, and iii) the emergence of pathogenic reversions seems to be a 
somewhat random event. Based on these finding, we speculate that the IC model allows for 
explosive expansion of the viral quasispecies before innate antiviral host responses can control 
the growth. During this time, there is relatively little selective pressure on the virus. Eventually 
host innate, and then adaptive, responses begin to cull mutants that most strongly elicit these 
responses. 
The emergence of pathogenesis could be explained by a number of phenomena: i) 
either random or selective pressure could lead to the selection of reversions at the sites of VEEV 
TrD attenuation, ii) there may be a selection of mutants that evade host detection or elicit non-
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protective responses, or iii) there may be a selection of mutants that strongly engage host 
responses leading to pathogenesis by from overly vigorous inflammatory responses. 
Additionally, it is interesting to consider whether pathogenesis observed in passaged VEEV TC-
83 IC challenge is due to a consistent defined set of mutations or a more random accumulation 
of minor pathogenesis contributors. Paradoxically, it has been noted that reduced fidelity of the 
viral replicase attenuates alphaviruses [350], however, we observed increased pathogenesis in 
VEEV TC-83 that seemed to have more genetic variability (Figure 17, 18).  
Sequencing of viral RNA isolated from necropsy brain samples of mice that received 
passaged VEEV TC-83 and met early euthanasia criteria, would provide insight to the nature of 
the pathogenic revisions we observed. Based on the recovered sequences, future experiments 
to document the time course of infection with these mutants could be designed. 
Additionally, many of these questions could be answered by set of passaging 
experiments with more passages from more individual donors that also incorporate serial 
sacrifice to collect RNA from the brain at multiple time points, followed by RNA-Seq analysis of 
the viral quasispecies and host responses. Presumably, there would be differences in host 
responses to either pathogenic or non-pathogenic passages of VEEV TC-83, especially at times 
after strong engagement of innate immunity. Perhaps more interesting is how much variation is 
there in the host responses to pathogenic passaged virus. As described here and previously, 
lethal viruses arose in 20%-40% of passages of VEEV-TC83 [36], but was not observed in the first 
two passages.  
Conclusions 
 ML29 was attenuated compared to MOPV in STAT-1-/- mice and did not show any signs 
of causing sensorineural hearing loss. Additionally, enhancing ML29 with the addition of DIPs 
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increased protective T-cell responses in this model. ML29 was also immunogenic in Hartley 
outbred guinea pigs, and neither ML29 nor ML29P50 displayed signs of renal or hepatic toxicity 
in this model. ML29P50 was deeply attenuated compared to ML29 both in vitro and in the highly 
sensitive CBA/J IC challenge model. Furthermore, the newly described L-segment derived MG 
system will be useful to study the mechanisms of DIP interference. ML29 is a broadly protective 
and safe vaccine against LASV and is an ideal candidate for further clinical developments.  
VEEV V4020 also an excellent candidate for clinical development. It is based on VEEV TC-
83 which has been used safely in human phase II trials, but further enhances safety. The mouse 
neuro-virulence data presented here, combined with the protective efficacy and favorable 
safety profile from the NHP study [323] support the application for US FDA investigational new 
drug status. 
In conclusion, this work builds upon two LAVs, ML29 and VEEV 4020, which are both 
based on attenuation of their respective wild-type viruses. Both were demonstrated favorable 
safety and immunogenicity using advanced small animal models, which makes them both 
excellent candidates for further vaccine development. 
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